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ABSTRACT 
 
Organ transplantation is the most effective and at times the only method for 
treating patients with end stage organ failure. Studies have shown that kidney 
transplants from living donors are consistently more successful and longer lasting 
than those from brain dead donors, regardless of the degree of HLA matching. With 
more than 90% of transplantable organs coming from deceased donors, it is of vital 
importance to study the causes of the deterioration within these organs. The 
purpose of my study was to mimic the clinical setting of brain death (BD) in a mouse 
model and, to use this model to study the effects of brain death on donor organs as 
well as examining these organs post-transplantation. We showed that brain death 
in this model was accompanied by the expected physiological changes, and that as 
reported for other similar models, a systemic pro-inflammatory state ensues, with 
release of alarmins including S100B and HMGB1, and rapid elevation in circulating 
levels of cytokines and chemokines such as IL-6, TNF-, IL-1, MCP-1 and KC. 
Biochemical evidence of kidney damage was provided by increased serum 
concentrations of NGAL, an early biomarker of acute kidney injury. 
After determining the optimum method for ureteric reconstruction, we collected 
kidneys from BD donors, and performed syngeneic renal transplants to examine 
how donor brain death amplifies the ischaemia-reperfusion injury which inevitably 
accompanies any transplantation procedure. As anticipated, we found that donor 
brain death resulted in upregulation of a number of pro-inflammatory cytokines 
 xxv 
 
and chemokines in transplanted kidneys, and in substantially increased infiltration 
with neutrophils and macrophages.   
It has been shown that esRAGE is capable of reducing inflammation by 
competitively binding to RAGE ligands. In order to study the effects of esRAGE upon 
IRI in brain-death and subsequent syngeneic renal transplantation, we generated an 
rAAV vector encoding esRAGE. Intraperitoneal injection of this vector resulted in 
strong, liver-specific expression of esRAGE. esRAGE significantly reduced the 
amount of HMGB1 in the serum of brain-dead mice. The most striking effect of 
esRAGE expression in mice undergoing brain death and syngeneic renal 
transplantation was a dramatic reduction in the numbers of infiltrating neutrophils 
and macrophages within the kidneys. Further, substantially increased numbers of 
proliferating cells were demonstrated in the kidneys of esRAGE-treated mice at d4 
after syngeneic transplantation from BD donors, compared with those of uninjected 
mice and particularly with those of mice receiving the control vector. Given that the 
grafts from esRAGE–treated mice had reduced numbers of infiltrating leucocytes 
compared to those in the other groups, these are likely to be renal parenchymal 
cells. These effects are likely to be translated into improved graft function, and 
augmented ability of the graft to sustain life. RAGE signaling on T cells contributes 
to adaptive immune responses, including alloresponses. Testing of esRAGE at later 
timepoints when the transplanted kidneys are life-sustaining and in allotransplant 
models where its effects upon the adaptive immune response are predicted to be 
additive to those on non antigen-specific graft inflammation is the logical next step 
for this line of investigation, and will shortly be undertaken.  
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CHAPTER 1: INTRODUCTION 
1.1 Deceased donor organ transplantation 
Organ transplantation is the most effective and at times the only method for 
treating patients with end stage organ failure. In Australia, in the year 2011, a total 
of 1,192 organs were transplanted which consisted of 586 kidneys, 199 livers, 66 
hearts, 306 lungs, 26 pancreas and 9 pancreatic islet grafts. Nonetheless, at the 
start of the year 2012, there were still 1518 patients on the organ transplantation 
waiting list [1]. This reflects not only the relative rarity of organ donation in 
Australia, compared with the incidence of end-stage organ failure, but also the 
need for re-transplantation following failure of the primary graft. Although 
transplantation is a well-established therapeutic modality, a number of challenges 
remain. Immunosuppressive drugs are used to dampen the host immune response 
and prolong graft survival. However, despite the introduction of increasingly 
powerful immunosuppressive regimes, long term graft survival has improved little 
over the past two decades [2-4]. The quality of the transplantable organ is emerging 
as an important factor in determining long term graft outcomes. A majority of the 
organs used for transplantation are donated from heart beating, brain dead donors. 
These organs are exposed to many insults, including brain death (BD) with 
catecholamine storm and vascular instability. Procurement, cold ischemia and 
transportation as well as warm ischemia and reperfusion in the recipient are also 
damaging to the transplantable organs. All these contribute to the ischemia 
reperfusion injury (IRI) which may potentiate graft rejection and oppose the 
2 
 
 
 
development of transplantation tolerance. Studies have shown that outcomes from 
organs of BD donors are significantly worse than those from living unrelated donors 
irrespective of the degree of HLA matching [5]. Understanding the mechanisms by 
which brain death damages donor organs will allow for the development of better 
therapeutic options for the management of deceased donors and ultimately will 
improve outcomes for transplant recipients. 
1.2 Outcomes of deceased donor organ transplantation 
Most organs for transplantation are procured from brain dead donors despite 
recent efforts to increase the rate of donation after circulatory death [6, 7]. BD in 
the donor is linked to impaired graft quality and is clinically associated with 
compromised patient and graft survival [8-12]. Despite advancements in 
immunosuppression, outcomes for patients receiving cadaveric organs are still 
consistently worse in both the short and long term than outcomes for those 
receiving organs from completely mismatched HLA living donors [5]. Similarly, 
patients with cadaveric organs experience more rejection episodes and are at a 
higher risk of primary graft failure [5, 8-10, 13-18]. According to the ANZDATA 
registry for the period 1991-2010, for kidney transplants performed on first time 
(primary transplant) recipients, the vast majority of the transplanted kidneys 
survived 1 year after transplantation with the survival rate from living donor 
kidneys being 96.8%, and that of deceased donor kidneys being 92.1%. From the 
same database, the 5-year survival rate for primary transplants is reported as 87.7% 
for living donor transplants and 80.9% for deceased donor transplants. Graft 
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survival rates progressively drop off 10, 15 and 20 years after transplantation. 
Nevertheless, primary transplants from a living donor on average result in longer 
transplant survival than deceased donor transplants [19]. This survival benefit 
extends to HLA mismatched living donors. These results are widely reflected by 
many animal studies [8, 16, 20-22]. 
1.3 Physiological changes of brain death 
The Cushing reflex is a well-recognised sign of brain death on the onset of raised 
intracranial pressure with a rise in systolic blood pressure. Brain death is 
accompanied by an immediate short period of hypertension and bradycardia 
followed by a massive release of catecholamines leading to vasoconstriction, 
fluctuations in blood pressure, endothelial injury, hypothermia, electrolyte 
abnormalities, tachyarrhythmias and coagulopathies [12, 23]. This phenomenon has 
been termed the ‘catecholamine storm’. Following this outpour of catecholamines, 
hypotension and reduced peripheral vascular resistance may result from a 
combination of the body failing to maintain circulating catecholamines and a loss of 
sympathetic tone [24-26]. Reduced oxygen delivery no longer meets myocardial 
oxygen demand causing global myocardial ischemia. This in turn further 
compromises the perfusion of peripheral organs, leading to endothelial activation 
and ischemia-reperfusion injury [27-31]. All of these processes contribute to a pro-
inflammatory environment in the donor, which has been demonstrated in various 
animal studies [22, 32, 33]. 
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Hormone depletion occurs as a result of pituitary infarction caused by brain death.  
The pituitary is a small gland connected to the hypothalamus and produces many of 
the hormones that control essential body processes. These include thyroid-
stimulating hormone (TSH), adrenocorticotrophic hormone (ACTH) and vasopressin, 
also known as anti-diuretic hormone. Deficiency of anti-diuretic hormone is 
manifested clinically as diabetes insipidus, where production of large volumes of 
dilute urine further destabilises fluid balance and end-organ perfusion [34]. 
1.4 Innate immunity in Brain Death and Ischemia Reperfusion Injury 
Allograft injury negatively affects both short and long term graft function, and 
amplifies graft rejection [35]. The causes of allograft injury can be linked to brain 
death, warm and cold ischemia and reperfusion [8-10, 13, 36, 37]. Peri-mortem 
events in BD donors lead to haemodynamic, hormonal, metabolic and inflammatory 
changes, all impacting the quality of transplantable organs and increasing graft 
immunogenicity. Many facets of the host immune system have been identified as 
contributors to the poor function of allografts. Initially, it was thought that the 
adaptive immune system was responsible for these effects but more recent findings 
have pointed towards the innate immune system playing an important role in both 
the acute and chronic rejection of allografts. The mechanisms by which donor 
organs are damaged include the up-regulation and activation of toll-like receptors 
and other pattern recognition receptors, release of cytokines and chemokines, 
upregulation of adhesion molecules and class II MHC on allograft endothelium and, 
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complement activation and thrombin deposition with depletion of tissue 
plasminogen activator [11, 12, 38-45]. 
1.5 Components of the innate immune response 
1.5.1 Pattern-recognition receptors 
Pattern-recognition receptors involved in innate immune responses include C-type 
lectin receptors, NOD-like receptors, RIG-like receptors, Toll-like receptors and 
RAGE [46]. Of these, the best characterised in terms of their role in ischaemia-
reperfusion injury of the various transplantable organs are the Toll-like receptors 
and RAGE. 
1.5.1a Toll-like receptors  
Toll like receptors (TLRs) are a set of germline-encoded receptors that play an 
important role in the innate immune response. They are expressed on a variety of 
cell types including macrophages, dendritic cells, neutrophils, B cells, NK cells, 
eosinophils, mast cells, basophils as well as on the parenchymal cells of some 
organs including tubular epithelial and mesangial cells within the kidney [47-49]. 
TLRs recognise conserved molecular patterns known as pathogen-associated 
molecular patterns (PAMPs) which are shared by large groups of microorganisms. 
They are also able to recognise endogenous ligands released by damaged tissues 
which are known as alarmins [50, 51]. Various alarmins have been implicated in TLR 
engagement. Some of these include high-mobility group box 1 (HMGB1), 
hyaluronan, fibrinogen, fibronectin, heparan sulphate, surfactant protein A and β-
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defensin 2 lymphoma antigen [43, 50, 52-57]. When TLRs are activated, adaptor 
molecules are recruited to the receptors through their respective Toll/Interleukin-1 
receptors (TIR) domain, which interacts with the TIR domains of TLRs. Myeloid 
differentiation factor 88 (MyD88) and TIR-domain-containing adapter-inducing 
interferon-β (TRIF) are the major adaptor molecules for TLRs, and TLR-activated 
signalling pathways can be classified into MyD88-dependent and –independent 
pathways, depending upon utilisation of these adaptors [58]. 
MyD88 recruitment predominates, and activates a downstream family of kinases, 
IL-1 receptor-associated kinases (IRAKs) 1, 2 and 4. Signalling events further 
downstream the release of NF-κB from inhibitor of NF-κB (IκB). The released NF-κB 
then moves to the nucleus and promotes an inflammatory response through 
increasing proinflammatory cytokine gene expression [58, 59]. TLRs can contribute 
to both innate and adaptive immune responses depending upon the cell types 
receiving signals. For instance, TLR4 engagement on renal tubular cells results in 
chemokine production and neutrophil recruitment, as well as the expression of 
activating ligands for natural killer cells, thus mainly influencing the innate response, 
illustrated in Figure 1 and 2 below. In contrast, TLR4 binding on dendritic cells 
potentiates adaptive immunity by upregulating MHC class II and co-stimulatory 
molecules which are important for antigen presentation to naïve T cells, and by 
modulating the expression of chemokine receptors CCR6 and CCR7, thereby 
directing the DC to the T cell regions of peripheral lymph nodes where antigen 
presentation can occur [60-62], Figure 3. 
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Figure 1 Downstream effects of TLR4 signalling on parenchymal cells. Engagement 
of TLR4 on renal tubular cells activates the MyD88-dependent pro-inflammatory 
pathway, resulting in the production of chemokines such as IL8, MCP-1 and RANTES 
and recruitment of neutrophils. At the same time, this engagement also results in 
the expression of activating ligands such as NKG2D, for natural killer (NK) cells, thus, 
mainly influencing the innate response. 
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Figure 2 Activation of the endothelium via TLRs and cytokines. An inflammatory 
response can occur through the engagement of TLRs and/or the binding of 
cytokines and chemokines, such as those released from TLR4 signalling on 
parenchymal cells (Figure 1), to the endothelium. Bound chemokines attract 
leucocytes and this, in turn, increases local levels of cytokines, such as TNF-α. The 
release of cytokines then up-regulates E-selectin and intercellular adhesion 
molecule-1 (ICAM-1) and this facilitates leucocyte migration into tissues.  
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Figure 3 Process of monocytes maturing into myeloid dendritic cells (DC) in 
response to TLR signalling. TLR binding on dendritic cells potentiates adaptive 
immunity by upregulating MHC class II and co-stimulatory molecules which are 
important for antigen presentation to naïve T cells, and by modulating the 
expression of chemokine receptors (decrease in CCR6 and increase in CCR7), 
thereby directing the DC to the T cell regions of peripheral lymph nodes where 
antigen presentation can occur. 
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TLRs are recognised as one of the most potent contributors to pathogen- and injury 
-induced inflammation. During IRI, both endogenous and exogenous ligands are 
released by damaged tissues which can bind to TLRs and in turn, activate the innate 
immune system [63].  
The expression and roles of TLR 2 and 4 have been widely studied in many organs 
following IRI. Studies have shown that TLR 4-dependent signals following IRI 
promote injury of the heart, lungs, liver and kidneys [24, 43, 44, 64, 65]. TLR 
engagement during IRI results in the release of proinflammatory cytokines and 
chemokines, with recruitment of neutrophils macrophages and T cells to the 
ischaemic tissues. In a positive feedback loop, cytokines such as IL-1β and TNF-α 
have been shown to further increase TLR 2 and TLR 4 mRNA levels in hepatocytes 
[66, 67]. Similarly, in kidneys, levels of TLR 2 and TLR 4 mRNA in the renal tubular 
epithelial cells are significantly increased by ischemia [68, 69]. Whereas TLR4 
deficiency was universally protective in renal, liver, lung or myocardial IRI, there are 
differences between organs in the relative importance of TLR4 engagement on 
different cell types, the contributions of the various adaptor molecules and the 
involvement of additional TLRs such as TLR2 in the pathogenesis of IRI. Ischaemic 
insults to the liver trigger innate immunity by activating TLRs in both parenchymal 
and nonparenchymal cells [43, 66, 67, 70], whereas in the kidney, signalling via TLRs 
on cells of the parenchymal compartment plays the predominant role in IRI 
propogation [42, 44]. Equivalent protection against renal IRI was afforded by either 
TLR4 or MyD88 deficiency [44], whilst Shigeoka et al showed that TLR 2 deficient 
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mice were better protected against IRI than MyD88 deficient mice, suggesting that 
the pathways contributing to TLR 2-mediated kidney damage following ischaemia 
involve other adaptors in addition to MyD88 [71]. Further studies attempting to 
determine the relative contributions of TLR 2 and 4 to renal IRI showed that IRI was 
attenuated in both single TLR 2 and TLR 4 deficient mice. Surprisingly, in mice with 
both TLR 2 and 4 deficiencies, no increased protection was observed when 
compared to the single TLR 2 or 4 deficient mice [72]. 
TLR 4-deficient mice exposed to warm liver ischaemia developed significantly less 
inflammation and hepatocellular damage than wild-type controls. However, In 
contrast to renal IRI, the liver injury was not reduced in MyD88 deficient mice [73], 
implying that TLR 4 induced inflammation in liver following ischaemia is mainly 
mediated via the MyD88 independent pathway. Similar to TLR 4, TLR 2 is an 
important player in the initiation of inflammation following renal ischaemia [42, 71]. 
Abrogation of TLR2 signalling by either genetic deficiency of TLR2 or antisense RNA 
treatment resulted in less tubular apoptosis, reduced cellular infiltrate, less renal 
damage and preservation of renal function [42]. Conversely no protective effect of 
TLR 2 deficiency could be demonstrated in a mouse model of liver IRI [74].  
1.5.1b RAGE 
The receptor for advanced glycation endproducts (RAGE) is a member of the 
immunoglobulin superfamily, encoded in the Class III region of the major 
histocompatability complex. The extracellular components of RAGE comprise an Ig 
variable domain (the principal site of ligand binding), VC1 and C2 domains, a 
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transmembrane region and a short intracellular tail. RAGE forms oligomers at the 
cell membrane, and dimerisation of RAGE via interaction of the V regions is 
essential for signal transduction through the cytoplasmic tail. The domain structure 
of RAGE is shown in Figure 4 below. 
 
     
Figure 4 The domain structure of RAGE.  
 
RAGE is a multiligand receptor which plays a crucial role in innate immunity against 
pathogens, but also interacts with endogenous ligands, resulting in chronic 
inflammation [75, 76]. RAGE is expressed in many tissues and cell types usually at 
low levels under steady-state conditions. RAGE is expressed in all transplantable 
organs, but is particularly abundant in lung where it is produced by type I alveolar 
epithelial cells [76-78]. Of note, RAGE becomes upregulated at sites where ligands 
accumulate [76-78]. RAGE recognises tertiary structures rather than amino acid 
(VC1) 
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sequences, thus, giving it the ability to engage classes of molecules rather than 
individual ligands [76, 78], a key feature of pattern-recognition receptors. RAGE 
binds inflammatory mediators of the S100 family and, in common with TLRs 2, 4 
and 9 is a receptor for HMGB1. Binding of ligands such as S100/calgranulins and 
HMGB1 to RAGE activates a range of signalling pathways depending on the cell 
types involved. Intermediates in these pathways include erk1/2 (p44/p42) MAP 
kinases, p38 and SAPK/JNK MAP kinases, rho GTPases, phosphoinositol-3 kinase, 
the JAK/STAT pathway and the downstream activation of NF-κB [78-83] leading to 
the production of pro-inflammatory cytokines, chemokines and adhesion molecules 
[75].  In addition to the upregulation of adhesion molecules which, in turn, 
promotes inflammatory cell recruitment, RAGE is directly involved in the 
recruitment of inflammatory cells as a counter-receptor for leukocyte integrins, 
interacting with β2-integrins [84]. RAGE suppression reduces the migration and 
proliferation of macrophages as well as the vascular expression of inflammatory 
molecules [85].  
RAGE exists in a number of isoforms. esRAGE is the major splice variant of RAGE 
and lacks the c-terminus of the full-length form, but isoforms lacking the N-
terminus and therefore without ligand binding activity exist, as does a dominant 
negative (DN) form with the transmembrane region but lacking the intracellular tail 
[86, 87]. 
The relationship between transmembrane and esRAGE is depicted below in Figure 5 
below.  
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Figure 5 Relationship between the transmembrane and esRAGE. 
 
Many of the isoforms of RAGE have regulatory effects upon RAGE signalling. DN 
RAGE binds ligands but cannot transduce a signal [86, 87]. esRAGE has been 
postulated to inhibit RAGE signaling via several distinct mechanisms.  esRAGE is a 
naturally-occurring decoy receptor which can bind to HMGB1, S100B, AGEs and 
other RAGE ligands. In healthy human subjects, plasma levels of HMGB1 are 
inversely related to those of esRAGE, suggesting that esRAGE mediates the 
clearance of HMGB1 from the circulation [88]. Soluble RAGE V domain binds to the 
V domain of TM RAGE, preventing dimerisation and thus blocking signal 
transduction [89]. Expression of RAGE is positively regulated by ligand binding, so 
that chronic administration of soluble RAGE in mouse models of diabetic 
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vasculopathy leads to clearance of RAGE ligands from the vessel wall, and to 
decreased RAGE expression [76]. 
During IRI, expression of RAGE and its ligands is significantly increased. Suppression 
of RAGE binding via the injection of soluble RAGE (sRAGE) decreases the infiltration 
of inflammatory effector cells into tissues along with decreased expression of 
proinflammatory cytokines [90, 91]. Administration of soluble RAGE promotes 
survival after partial warm liver IRI and resection of the non-ischaemic fragment. In 
a seeming paradox, levels of some inflammatory cytokines such as IL-6 and TNF-
alpha was increased by sRAGE treatment. Proliferation of hepatocytes was also 
increased [92]. 
1.5.2 Danger signals or “alarmins” 
Alarmins are endogenous mediators that can simultaneously induce the 
chemotactic migration and activation of antigen-presenting cells (APCs), and 
consequently promote the induction of immune responses [93, 94]. They are 
present in leukocytes and various epithelial cells as either granular products or 
nuclear proteins which are produced rapidly by cells of the host innate immune 
system in response to infections and/or tissue injuries. Alarmins include defensins, 
cathelicidin, eosinophil-derived neurotoxin (EDN) and high-mobility group box 1 
(HMGB1) protein. They function not only as potent effectors of innate defence but 
also act to alarm the immune system by promoting the recruitment and activation 
of host leukocytes through interaction with distinct receptors.  
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1.5.2a High mobility group box 1 
High mobility group box 1 (HMGB1) is a nuclear protein that is released upon cell 
stress or necrosis, and when extracellular, can exert proinflammatory activities [43, 
71, 79, 90, 95, 96].  Apoptotic cells do not release HMGB1 upon death as they 
modify their chromatin to bind to HMGB1 tightly [65]. HMGB1 can form specific 
complexes with various molecules such as ssDNA, LPS, IL-1β and nucleosomes 
which interact with TLR 9, TLR 4, IL 1R and TLR 2 respectively [48, 54, 97]. These 
complexes elicit a much greater inflammatory response than those due to the 
uncomplexed danger signal. As an example, as little as 0.5 ng/ml LPS associated 
with 0.5 µg/ml HMGB1 induces levels of IL-6 release comparable to those produced 
by 100 ng/ml of LPS alone [55]. HMGB1 can also bind to RAGE to induce 
inflammatory responses. Amplification of inflammatory responses to CpG DNA in 
the presence of HMGB1 involves physical association and co-operation between 
HMGB1 and RAGE [98]. It has not been determined whether similar mechanisms 
account for the synergistic interactions between HMGB1 and the ligands for TLRs 2 
and 4.  
HMGB1 is upregulated in ischaemic mouse kidneys, both at the mRNA and at the 
protein level [44]. During IRI, HMGB1 induces DC cell maturation as well as 
promotes the secretion of proinflammatory cytokines [68, 70, 99]. Adhesion and 
migration of macrophages and neutrophils is increased upon stimulation with 
HMGB1 [69, 100, 101]. In part, this is due to the interaction of MAC-1 and RAGE, 
thus, activating the adhesive and migratory function of these cells [102]. 
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Furthermore, HMGB1 with the help of neutrophils stimulates production of reactive 
oxygen species through a TLR 4 dependent activation of NAD(P)H oxidase as well as 
increases activation of NF-κB, resulting in production and release of cytokines [67, 
103]. 
Many studies using HMGB1 neutralizing antibodies in mice have shown lessening of 
damage and inflammation following IRI. Wu et al showed that treating mice with 
neutralizing anti-HMGB1 antibody protected them against kidney IRI, mediated by 
HMGB1/TLR 4 signalling through the MyD88 dependent pathway, reflected in lower 
serum creatinine level, less tubular damage, less neutrophil and macrophage 
infiltrates and significantly reduced apoptosis of tubular epithelial cells than 
untreated mice [44, 104]. In liver, HMGB1 acts as an early mediator of inflammation 
and organ damage as early as 1 hour after reperfusion and up to 24 hours. When 
mice were treated with HMGB1 neutralizing antibodies, significantly less damage 
was observed after liver IRI, whereas administration of recombinant HMGB1 
worsened IRI [77, 97]. This worsening may, in part, be caused by HMGB1 interacting 
with functional TLR 4 on dendritic cells (DCs) [105]. However, in a seeming paradox, 
preconditioning with HMGB1 conferred protection against hepatic IRI. This 
protection was associated with higher expression of IL-1R-associated kinase M 
which is a negative regulator of TLR 4 [97].  
In a porcine model of brain death, HMGB1 expression is upregulated in the liver and 
kidney within hours of after brain death induction [38]. Moreover, immunostaining 
demonstrates that early HMGB1 migration out of the nucleus and into the 
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cytoplasm, an appearance which correlates with its release and function as an 
alarmin [43]. TLR4 but not TLR2 was strongly upregulated in both liver and kidney 
early after brain death. Brain death differs from warm ischaemia of isolated 
individual organs in that the erratic peripheral perfusion which accompanies brain 
death can compromise gut integrity, resulting in translocation of bacterial products 
and elevated endotoxin levels in the systemic circulation [106, 107]. The kidneys 
normally express high levels of TIR8, an inhibitory receptor which dampens TLR 
signalling by sequestering signalling intermediates such as IRAK-1 and TRAF-6 [108]. 
Endotoxin downregulates TIR-8 expression, thus, releasing TLR signalling from 
inhibition, as well as acting as an agonist for TLR4 [108]. The convergence of 
HMGB1 release and systemic endotoxaemia which occur during brain death imply 
that HMGB1-LPS complexes should be potent stimulators of TLR4 signalling, and 
that interruption of this pathway will attenuate inflammation in donor kidneys 
following brain death. 
1.5.2b S100B 
S100B is a protein belonging to the family of S100/calgranulins and is also a ligand 
of RAGE. It is particularly abundant within astroglia of the CNS, but also found in 
many other tissues and cells including dendritic cells, langerhans cells, and 
mononuclear phagocytes, myocardium, renal epithelium, adipocytes, melanocytes 
and chondrocytes [109]. S100B is released into the systemic circulation during 
acute brain injury, is detectable in peripheral blood samples following brain death 
and has been proposed as a potential biomarker for the severity of CNS injury [110]. 
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S100B is also released from other organs upon damage and is mainly eliminated in 
the kidney [109, 111]. Intracellular S100B is responsible for the regulation of 
cytoskeletal structure and cell proliferation but high levels have deleterious effects 
[112, 113]. At high extracellular levels, S100B stimulates endothelial, vascular 
smooth muscle cells, monocytes, macrophages and T cells via RAGE which results in 
the generation of cytokines, chemokines and proinflammatory adhesion molecules 
[84, 90, 91, 114], recruits inflammatory cells to sites of tissue damage and induces 
apoptosis [115]. Apoptotic death also results from RAGE signalling with 
downstream elevation of reactive oxygen species, cytochrome C release and 
activation of the caspase cascade [113]. During brain death, S100b is primarily 
released by cells in the CNS but can also be readily released from other tissues 
undergoing ischaemic injury subsequent to the initial CNS damage.  
1.5.3 Effector cells of the innate immune response 
Many cells play part in the innate immune response. During IRI, neutrophils, 
macrophages, natural killer (NK) cells and also T cells, in particular CD4+ and CD8+, 
which are derived from pluripotent stem cells in bone marrow, are rapidly recruited 
to the site of injury [116].  
1.5.3a Neutrophils  
Neutrophils form the first and most prominent line of cellular defense against 
invading microorganisms and injury. Active recruitment of neutrophils to the site of 
injury is important to the innate immune system. Neutrophils are mobilized from 
20 
 
 
 
circulation and bone marrow reserves in response to host-derived chemotactic 
factors. Neutrophils roll along the walls of postcapillary venules, surveying 
connective tissue, mucosal membranes, skeletal muscle, and lymphatic organs for 
signs of tissue distress and the presence of chemoattractants [117]. Some of the 
well-studied neutrophil chemoattractants are IL8, INF-γ, C5a and leukotriene [118-
121]. Once at the site of injury, neutrophils can be primed for enhanced adhesion, 
phagocytosis, production of reactive oxygen species (ROS), cytokine secretion, 
leukotriene synthesis, degranulation and bactericidal activity [122-124].  
Neutrophils can function at the site of injury by binding and ingesting the invading 
cells by the process of phagocytosis. Neutrophils are able to directly recognize 
surface-bound or freely secreted molecules produced by bacteria, including 
peptidoglycan, lipoproteins, lipoteichoic acid, lipopolysaccharide (LPS), CpG-
containing DNA and flagellin. These molecules produced by bacteria are known as 
PAMPs and can interact directly with TLRs expressed on neutrophils [125, 126]. 
Ligation of neutrophil TLRs, in particular TLRs 2 and 4, activates transduction 
pathways that ultimately prolong cell survival, facilitate adhesion and phagocytosis, 
and enhance release of cytokines and chemokines [125, 127, 128]. 
Alternatively, under the condition of IRI, neutrophils can be activated through the 
release of oxygen free radicals, cytokines and proinflammatory mediators [129, 
130]. The activation of neutrophils brings about an inflammatory-like response and 
plays a central role in releasing oxidants and proteases that damage or kill tissues, 
and release inflammatory products, such as TNF-α and IL6, that amplify the 
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recruitment and activation of greater numbers of neutrophils into the effected 
tissue, thereby extending the severity of tissue damage [131, 132]. 
1.5.3b Macrophages 
Monocytes circulate in the blood stream. In response to infection or an 
inflammatory stimulus, monocytes migrate to the site of the immune-inflammatory 
activity where they differentiate into macrophages [133]. They play an important 
role in host defense against microorganisms and in the removal of senescent 
erythrocytes and leukocytes [134, 135]. Their primary modes of action are 
phagocytosis and subsequent digestion, antigen presentation and cytokine 
production. Macrophages can perform phagocytosis of opsonized microbes or via 
binding of PRRs to microbe-associated molecular patterns (MAMPs). Microbial 
fragments that remain after digestion are served as antigen. The fragments are 
incorporated into major histocompatibility complex (MHC) molecules and then 
transported to the cell surface of the phagocyte. This process leads to the activation 
of T lymphocytes, which then mount a specific immune response against the source 
of the antigen. Microbial products can directly activate macrophages leading to the 
production of pro-inflammatory cytokines. Typical cytokines produced by 
macrophages include TNF, IL1, IL6 and IL12 [136-138]. 
1.5.3c Natural Killer (NK) cells 
NK cells have an important role in the innate immune system because they are able 
to recognize infected cells, cancer cells and stressed cells, and kill them. In addition, 
they are able to produce a variety of cytokines, including proinflammatory 
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cytokines, chemokines, colony-stimulating factors, and other cytokines that 
function as regulators of body defenses. Through cytokine production, NK cells are 
also able to suppress and/or activate macrophages, suppress and/or activate the 
antigen-presenting capabilities of dendritic cells, and suppress and/or activate T-
lymphocyte responses [139, 140].  
NK cells use a dual receptor system in determining whether to kill or not kill a cell. 
When cells are either under stress, are undergoing malignant transformation, or are 
infected, various stress-induced molecules such as MHC class I polypeptide-related 
sequence A (MICA) and MHC class I polypeptide-related sequence B (MICB) are 
produced and expressed on the surface of those cells [141, 142]. The first type of 
receptor on NK cells, called the killer-activating receptors (KAR), can bind to these 
stress-induced molecules, and this sends a positive signal that enables the NK cell to 
kill the cell to which it has bound unless the second receptor cancels that signal. 
The second receptor type, called the killer-inhibitory receptors (KIR), are able to 
recognize MHC-I molecules [143]. This helps NK cells distinguish between self and 
non-self. If the self MHC-I molecules have peptides from the body's own proteins 
bound to them, NK cells will recognize those cells as self, and the receptor triggers a 
negative signal that overrides the original kill signal and prevents the NK cell from 
killing the target cell to which it has bound. On the other hand, if the MHC-I 
molecules have peptides from viral, bacterial, or mutant proteins bound to them, 
NK cells may fail to recognize that cell as self and kill it [143].  
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NK cells can destroy target cells in two ways. The first is via the release of pore-
forming proteins called perforins, proteolytic enzymes called granzymes, and 
chemokines. Granzymes pass through the pores and activate the enzymes that lead 
to apoptosis of the infected cell by means of destruction of its structural 
cytoskeleton proteins and by chromosomal degradation [144]. As a result, the cell 
breaks into fragments that are subsequently removed by phagocytes. The second is 
by binding of the Fas ligand (FasL) of NK cells to Fas of the target cell. This binding 
causes a conformational change in Fas, making it bind to the death domain, and 
sending downstream signals to induce apoptosis by a caspase-dependent process 
[145]. 
 
 
Figure 6 NK cell interacting with a normal body cell [146].  
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Figure 7 Two mechanisms NK cells utilize to destroy target cells [147]. The first 
mechanism in which NK cells are capable of destroying target cells is by the release 
of perforins and granzymes. Granzymes pass through the pores, created by 
perforins, and activate the enzymes that lead to apoptosis of the target cell. The 
second mechanism is binding of NK cell FasL to target cell Fas. This process sends 
downstream caspase-dependent signaling in the target cell leading to the induction 
of apoptosis.  
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1.5.3d T cells 
Although T cells are principally thought of as components of the adaptive immune 
system, both CD4+ and CD8+ T cells also contribute to the innate immune system. 
CD4+ T cells are capable of producing proinflammatory cytokines and cellular 
immune responses whilst CD8+ T cells, also known as cytotoxic T cells (CTL), are very 
capable as effectors of target cell destruction, and function like NK cells (Figure 7 
above). The cytokines released by CD4+ T cells promote the activation and 
proliferation of cytotoxic T cells and NK cells as well as the recruitment and 
activation of macrophages, described in Figure 8 below. 
 
Figure 8 Pathways utilized by CD4+ T cells to destroy target cell. CD4+ T cells are 
capable of releasing Th1 cytokines used to activate CD8+ T cells and, at the same 
time, assist with the recruitment and activation of macrophages. They are also able 
to release Th2 cytokines which mature B cells into antibody-producing plasma cells, 
contributing to antibody-dependent cellular cytotoxicity.  
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The role of T cells in innate immunity has been shown in a number of animal studies. 
T cells are mediators of IRI in mice. Studies using T cell-deficient mice showed 
better outcomes for both liver and renal IRI [148, 149]. Further study into the roles 
of the T cell subsets, CD4+ and CD8+, showed that organs from mice deficient in 
CD4+ T cells, but not mice deficient in CD8+ T cells, were significantly protected 
against IRI [148]. These results were confirmed by the reconstitution of CD4-
deficient mice with wild-type CD4+ T cells where the cellular inoculum restored 
renal injury [148]. The mechanism by which CD4-deficent mice are protects against 
renal IRI is dependent on CD28 and IFN- γ. CD4-deficent mice adoptively transferred 
with enriched CD4+ T cell lacking in either CD28 or IFN-γ retained protective effects 
against renal IRI in both cases [148]. However, this finding was not replicated in 
liver IRI. Blocking of CD4-derived IFN-γ signaling in liver IRI was not seen to have any 
protective effects [150]. Rather, the mechanism by which CD4-deficient mice are 
protected against liver IRI is dependent on CD154 and CD28 [150].  Shen et al., 
showed that, in liver IRI, CD4+ T cells functions are dependent on CD154-CD40 
signaling. They also showed that CD4+ T cells can function in liver IRI without the 
requirement of de novo Ag-specific activation [150]. 
1.6 Pathological features of renal and liver warm IRI. 
IRI is the tissue damage that ensues following reperfusion of ischaemic tissues. 
Whilst prolonged anoxia results in cell death, tissues experiencing sub-critical 
ischaemic periods may still receive a lethal injury after restoration of blood supply 
to them. This is the ischaemia-reperfusion injury, a phenomenon that appears to be 
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mediated by inflammatory processes. A proposed cascade of IRI sees accumulation 
of free radicals and anaerobic metabolites during the ischaemic period. Upon 
restoration of blood supply, oxidative cell damage occurs, resulting in cytokine and 
adhesion molecule synthesis and activation. This in turn attracts leucocytes to the 
reperfused tissues, and thus ensues cellular damage and necrosis. The mechanisms 
of this leucocyte-mediated cell damage are multiple and include microvascular 
occlusion, oxygen free radical damage, cytotoxic enzyme release, increased 
cytokine release and increased vascular permeability [151-155]. Despite the 
necessity of restoration of blood supply for tissue survival, the event of reperfusion 
can, paradoxically, exacerbate the cellular injury [156]. 
1.7 Innate immunity opposing tolerance 
TLR-mediated signalling has been shown in a number of studies to have an 
inhibitory effect upon the induction of transplantation tolerance [157, 158]. Studies 
using small animal models have shown that administration of Pam3CSK4, 
lipopolysaccharide (LPS) and CpG-ODN, agonists to TLR 2, 4 and 9 respectively, 
promotes allograft rejection. In the absence of TLR signalling, anti-CD154-treated 
animals sustain long term cardiac graft survival assisted by the recruitment of Tregs 
to heart allografts. Nonetheless, engagement of a single TLR (TLR9) by CpG-ODN 
was all it took to abrogate this anti-CD154- mediated survival prolongation, via 
mechanisms including reduced recruitment of CD4+/FoxP3+ Tregs [159, 160]. In 
subsequent studies, Chen et al were able to demonstrate that CpG functions by 
targeting recipient hemopoietic cells and promotes acute cardiac allograft rejection 
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in a manner that depends on IL6 and IL17, and that its pro-rejection effects 
correlate both with prevention of anti-CD154-mediated conversion of conventional 
CD4+ T cells into induced regulatory T cells and with the expression of IFN-γ and IL-
17 by intragraft CD4+ T cells [161]. Further studies in the same model demonstrated 
that the elimination of IL6 and IL17 signalling suppressed the ability of CpG to 
promote cardiac allograft rejection [161]. 
Donor brain death results in upregulation within and release from the 
transplantable organs of TLR ligands such as HMGB1 [38]. The erratic peripheral 
perfusion that occurs with BD can compromise gut integrity resulting in 
translocation of LPS and other bacterial products into the systemic circulation. Thus 
it seems highly likely that the inflammatory processes triggered by donor brain 
death could impede the development of transplantation tolerance. 
1.8 rAAV vectors for gene transfer to the liver 
AAV posesses many qualities ideally suited for gene transfer. It is non-pathogenic 
and naturally replication-deficient, with a low risk of insertional mutagenesis. 
Vector safety is further enhanced by removal of all virus coding sequences leaving 
only the 145-nucleotide ITRs required for genome packaging [162]. Liver-directed 
transgene delivery in mouse models has been shown to result in tolerance to a 
number of expressed proteins, both secreted and cytosolic [162]. Studies using 
mice transgenic for the D011.10 T cell receptor which specifically recognizes 
chicken ovalbumin (OVA) demonstrated antigen-specific CD4+ T cell anergy and 
deletion following AAV-mediated liver-specific expression of OVA. The proportion 
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of thymocytes expressing the D011.10 receptor declined over time, suggesting that 
central, as well as peripheral, deletion was occurring. Moreover, these mice failed 
to produce anti-OVA antibodies after a subsequent challenge with OVA, implying 
that the absence of T cell help resulted in operational B cell tolerance. Similarly, 
wild-type mice did not produce antibodies upon challenge with Factor IX (F.IX) 
following AAV-mediated expression of this antigen in the liver [163]. Cytotoxic T cell 
responses to transgene products are also abrogated in mice by liver-specific gene 
expression [164-167]. 
In contrast to skeletal muscle expression of these genes, challenge with a highly-
immunogenic adenoviral vector following earlier AAV-mediated liver-specific 
expression of the same transgene does not result in the destruction of transduced 
hepatocytes [164]. Tolerance induction after hepatic gene transfer is promoted by 
higher levels of gene expression. For each transgene, a threshold level of expression 
exists, below which tolerance cannot be achieved [162]. The combination of AAV8 
capsid with the efficient liver-specific ApoE/hAAT promoter results in substantially 
higher levels of transgene expression at equivalent vector doses, when compared 
with AAV2-ApoE2/hAAT [167]. Correspondingly, AAV8-ApoE2/hAAT-driven gene 
transfer was superior to that mediated by AAV2-ApoE2/hAAT in inducing tolerance 
to Human F.IX across a range of F.IX-deficient mouse strains, including C3H/HeJ F9-/- 
mice which had previously been resistant to tolerance induction [167]. An AAV2 
vector genome pseudo-serotyped with the type 8 capsid (rAAV2/8), and 
incorporating the human α-1 antitrypsin (hAAT) promoter has been used 
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extensively in the sponsoring laboratory. In our hands, this vector provides high-
level, long-lasting liver-specific transgene expression, with no inflammation in 
rodent livers expressing a range of proteins including GFP, indoleamine dioxygenase 
[168], esRAGE, human albumin, or allogeneic mouse MHC [169]. In the latter study, 
tolerance to the transgene products has been formally demonstrated. For these 
reasons, I chose to use the rAAV2/8 system for systemic overexpression of esRAGE 
in mice in the present project. 
1.9 Systemic overexpression of esRAGE as a strategy to block innate signalling in 
brain death and ischemia-reperfusion injury 
The systemic overexpression of esRAGE had been proposed and shown in our lab to 
block innate signalling in renal IRI [170]. Our lab showed that overexpression of 
esRAGE significantly reduced tubular damage and reduced serum creatinine levels 
in IRI when compared to uninjected and sham controls. We also showed that 
overexpression of esRAGE significantly increased survival in severe renal IRI and 
preserved renal morphology. These encouraging results suggested that esRAGE 
expression could potentially also attenuate inflammation, improve graft function, 
and promote tolerance induction in kidneys transplanted from brain-dead donors, 
and prompted me to undertake this project. 
1.10 Hypotheses and Aims 
We hypothesised that donor brain death would result in increased inflammation in 
and hence poorer function of kidneys transplanted from brain dead donors. Our 
second hypothesis was that systemic overexpression of esRAGE mediated by 
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administration of a rAAV 2/8 vector would attenuate inflammation and preserve 
function of such kidneys.  
In order to test these hypotheses, we aimed to: 
1. Establish and characterise a murine model of brain death (Chapter 5). 
2. Determine the optimum method of ureteric reconstruction for use in mouse 
renal transplantation from brain dead donors (Chapter 4). 
3. Develop a method for systemic overexpression of esRAGE (Chapter 3). 
4. Determine whether systemic overexpression of esRAGE attenuates 
inflammation after donor BD and renal transplantation (Chapter 6). 
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CHAPTER 2: MATERIALS AND METHODS 
2.1 Development of a Brain Death Model in Mice 
Although this model was based upon the published protocol of Atkinson et al. [23], 
a number of refinements were introduced throughout the development of the 
model. The modifications made in order to produce a functional and reproducible 
model of brain death in mice are described below. 
2.1.1 Anaesthesia 
In the initial stages of the development of the model, mice were induced and 
maintained under anaesthesia with inhalational Isoflurane 1.5-2.5% (Baxter 
Healthcare, Auckland, NZ). The anaesthetic agent is administered through a nose 
cone using an oxygen flow rate of 1L/min. This method of anaesthesia is well 
established for small animal surgery and is the standard practice within our 
laboratory. It soon came to our attention that using inhalational anaesthesia is not 
practical for this model of brain death as obstruction by the nose cone makes 
drilling the burr hole near impossible and tracheostomy difficult. Additionally, 
isoflurane induces BP fluctuation, most likely due to its cardiodepressant effects, 
thus, further decreasing its suitability as BP is inherently unstable following the 
onset of brain death and cannot be maintained in the face of this additional 
challenge.  
The alternative we decided to use was an IP injection of a mixture of Ketamine 
(Hospira Australia, VIC, Australia) (81mg/kg) and Xylazine (Troy Laboratories, NSW, 
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Australia) (9mg/kg). Initially the mouse would be injected IP with the 
Ketamine/Xylazine mixture to induce anaesthesia. The depth of the sedation was 
monitored every few minutes and before any invasive procedure through the 
withdrawal reflex and the observation of the whiskers of the mouse. Movement of 
the whiskers upon stimulation is a sign of shallow anaesthesia and a top-up dose of 
half the initial dose of Ketamine (40.5mg/kg) would be injected alone. We inject 
only Ketamine in this first top-up dose because the effect of Xylazine last twice as 
long as Ketamine. For the second top-up, half the initial dose of Ketamine 
(40.5mg/kg)/Xylazine (4.5mg/kg) mixture is injected IP.  
2.1.2 Ventilation 
The Inspira advanced safety rodent ventilator (Harvard Apparatus, MA, USA) was 
used for ventilation with an FIO2 of 60%. The ventilator tubing was attached to a 
22G blunt tipped cannula (BD Medical, MC, USA) used for insertion into the trachea. 
The ventilator auto-adjusts its ventilation settings according to the input weights of 
the mice. Pressure-controlled mechanical ventilation was substantially better than 
volume-controlled ventilation at maintaining good oxygen saturation in the mice. 
As a further refinement, a small amount of positive end-expiratory pressure (PEEP) 
(5-7 cmH2O) was added to the ventilator settings. Final settings for the ventilator 
were pressure-controlled mechanical ventilation with a PEEP of 5cmH2O with the 
manual input of individual mouse weight for ventilator to auto-adjust itself suitably. 
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2.1.3 Brain Death Induction 
The induction of brain death was performed in a similar manner to that described in 
other protocols for induction of brain death in rodents. The method used involves 
inserting a 2F Fogarty catheter (LeMaitre Vascular, MA, USA) into the intracranial 
cavity through a burr hole. The balloon of the Fogarty catheter is slowly inflated to 
progressively increase intracranial pressure leading to brain stem herniation and 
irreversible brain death.  
The burr hole was sited in the right parasagittal bone, shown Figure 9A below. 
 
 
Figure 9 Creation of burr hole. A - Theoretical location of burr hole marked by “X”; 
B - Actual burr hole made in mice. 
 
A  B 
35 
 
 
 
The initial approach we took for making the burr hole was by the use of a 
mechanical drill. The overlying skin over the skull would be cut open, followed by 
the drilling.  
Despite a sufficient-sized burr hole being made, much is at risk. This method proved 
unsuitable as the speed of the rotary drill was difficult to control and the drill bit 
would often catch onto the surrounding scalp tissues, ripping them apart and 
causing intractable bleeding. Additionally, there is a risk of drilling beyond the thin 
layer of skull and into the cerebral cortex, a complication which is well documented 
in the Pratschke et al model of brain death in rats [16]. Because of the hazards of 
using this method of drilling, we decided explore to an alternative. 
Due to the small size of the 2F Fogarty catheter, we decided to try use the stylet 
(needle) of a 14G cannula (TERUMO, Phillipines) as a hand drill. We chose 14G 
because its external diameter is only slightly bigger than the Fogarty catheter, 
allowing a good seal after insertion of the catheter. Slight downward pressure is 
applied to the 14G cannula stylet onto the skull whilst making a slow rotary motion 
with the hand. Once an impression is made on the periosteum, the stylet is angled 
at 45 degrees, and drilling continues until the skull, but not the dura mater, is 
perforated, Figure 9B above. The Fogarty catheter is then inserted and secured to 
the back of the mouse with a masking tape. This procedure is much gentler than 
mechanical drilling, and associated with less chance of causing complications like 
intractable bleeding and penetration of the cortical brain tissue.  
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The method of inflation of the Fogarty catheter has also been modified. Initially we 
inflated the Fogarty catheter by hand with 80µl +/- 25µl saline over a period of 15 
minutes (based on Atkinson et al). Though we achieved brain death through this 
method, it was very difficult to maintain a constant rate of inflation, as a sudden 
drop in resistance of the balloon was usually accompanied by a rapid increase in 
volume, leading to explosive as opposed to gradual brain death. Mice would often 
die immediately post-BD induction. Reflecting our findings, earlier studies had 
shown that dogs undergoing explosive brain death experienced significantly more 
myocardial ischemia and arrhythmias and were more vulnerable to haemodynamic 
complication than those undergoing gradual brain death [21]. Based on these 
studies and our results, we decided it was vital to keep the inflation of the balloon 
constant and started using a syringe driver. The syringe connected to the Fogarty 
catheter was placed into an automated syringe driver (Harvard Apparatus, MA, USA) 
and the saline was infused into the balloon at a constant rate of 5µl/min over 20 
minutes up to a maximum of 100µl. Inflation was ceased at the point where mean 
arterial pressure (MAP) started rising rapidly (see Figure 11 below). This was 
accompanied by a permanent increase in heart rate (HR), followed by a slow 
decline in MAP over the subsequent hours (Figure 11). 
2.1.4 Fluid Support 
We initially decided to use normal saline injected both IV and SC as fluid support. 
Mice, at the start of the experiment, would be injected with 0.5ml IV through the 
penile vein and 2.0ml SC at four different sites, i.e. 0.5ml SC at each site. Fluid top-
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up would occur at hourly intervals from the start of the experiment for the SC 
injection with 1.5ml at three different sites. IV fluid top-ups of 0.5ml would occur 
once after the femoral artery cannulation and then at 30 minute intervals 
thereafter. At the beginning, we tested with mice that were ventilated alone. The 
fluid support seemed sufficient and mice were able to be maintained for the 
desired duration of 3 hours, shown in Figure 10A below. When we first attempted 
maintaining the BD mice, we found that this fluid support regime did not maintain 
intravascular volume, and mice would desaturate rapidly following the induction of 
BD (Figure 10B). Post mortem dissection found evidence of pulmonary oedema, 
with heavy, engorged lungs which sank rapidly upon placement in formalin. The 
pulmonary oedema observed may have been due to a number of factors including 
fluid overload, left ventricular failure, oncotic dilution or due to neurogenic 
pulmonary oedema.  
To avoid reducing the plasma oncotic pressure by dilution, we decided to try using a 
colloid fluid instead of saline, a crystalloid. The colloid solution we chose to use was 
Gelofusine (B.Braun, AG, Germany), a colloidal plasma volume replacement fluid 
based on modified fluid gelatine which has iso-oncotic pressure, physiological pH 
and a low chloride content. 
We started by using one bolus of 0.5ml IV Gelofusine and 2.0ml SC of normal saline 
at four sites. Following the initial bolus, we topped up at hourly intervals with 1.5ml 
of normal saline SC divided amongst three sites. Further IV boluses of 0.25ml 
Gelofusine were given following femoral artery cannulation if the MAP was below 
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55mmHg, and then as required when the MAP dropped to 40mmHg or below. This 
type of fluid support was able to maintain blood pressure in the mice without 
compromising oxygenation for up to 3 hours, shown in Figure 11 below. 
 
 
Figure 10 Saline IV as fluid support for ventilated only 3 hours (A) compared to 3 
hours of BD (B). A - Fluid support seemed sufficient and mice were able to be 
maintained for the desired duration of 3 hours in the ventilated group; B - Fluid 
support regime did not maintain intravascular volume, and mice would desaturate 
rapidly following the induction of BD. 
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Figure 11 Traces for optimized model of BD with Gelofusine as fluid support. BP 
peaked rapidly at point of BD. This was accompanied by a permanent increase in HR, 
followed by a slow decline in BP over the subsequent hours. Using Gelofusine 
maintained blood pressure without compromising oxygen saturation. Temperature 
well maintained between 37oC to 38.5oC.  
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2.1.5 Body Temperature 
Core temperature was measured using a rectal probe (Columbus Instruments, Ohio, 
USA), and was maintained within the range of 37oC to 38.5oC (Figure 11 above) 
using a heating pad (Redzone Heating, Australia). Temperature was displayed on a 
Physiomex small animal physiological monitor (Columbus Instruments, Ohio, USA). 
2.2 The Functional BD Model 
All procedures performed below were done on C57BL/6 male mice. Following 
anaesthesia with Ketamine and Xylazine, the left thighs of the mice were shaved in 
preparation for femoral artery cannulation. 
Once the preparation had been completed, mice were placed in a ventral position.  
The skin above the skull was cleaned with 70%. The skin was opened with a vertical 
incision. Once opened, a 14G cannula stylet was used to drill a burr hole in the 
bottom left corner of the right parasagittal bone of the skull, Figure 9B above. A 2F 
Fogarty balloon catheter was then inserted into the burr hole and secured by the 
use of masking tape, sticking the catheter to the mouse’s back. Brain death will be 
induced after mechanical ventilation and invasive BP monitoring have been 
established. Upon completion of the burr hole, mice were placed back into dorsal 
position. The mice were secured with masking tape to the working surface. A rectal 
thermometer was then inserted. Next, the neck skin was sprayed with 70% ethanol. 
A vertical midline incision was made in the anterior neck. The two halves of the 
sternohyoid muscle were then separated and trachea exposed. A loose 5-0 silk tie 
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was then placed around the trachea. The ventilator was set to pressure controlled 
ventilation with mouse weight entered, PEEP of 5cmH2O and FIO2 60%, and gas 
flow was started. A small transverse incision was then made in the sub-laryngeal 
area between two rings of cartilage, see Figure 12A below. The 22G blunt tipped 
cannula attached to the ventilator tubing was then inserted into the trachea to a 
pre-determined mark, avoiding cannulation of either main bronchus and ensuring 
ventilation of both lungs. The cannula was then secured with the loose tie. An 
additional 5-0 silk tie was then placed around the trachea and cannula to maintain a 
snug fit preventing gas leakage, see Figure 12B below.  
 
 
Figure 12 Depiction of tracheostomy. A - The exposure and opening of trachea; B - 
The securing of the ventilator tube to the trachea.  
 B  A 
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The last surgical procedure was the cannulation of the left femoral artery. This 
procedure was required for monitoring the MAP. The shaved left thigh was used. 
An incision was made in the left inguinal area. The femoral neurovascular bundle 
was exposed using blunt dissection with cotton buds (Figure 13A). The femoral 
artery was then separated from the surrounding tissues and vessels in the area 
between the abdominal wall and the superficial epigastric artery, see Figure 13B 
below. Lignocaine was used to help prevent artery vasospasm. Once separated, the 
distal end of the femoral artery was ligated with a 5-0 silk tie, slightly retracted with 
a clamp. A 5-0 silk tie was also placed around the proximal end of the artery, with a 
loose knot. This tie was also retracted and elevated using a clamp until the point 
where blood stopped running into the area in between the two ties, see Figure 14B 
and Step 1 of Figure 14A. A small transverse incision going half way across the 
femoral artery was made 2mm proximal to the distal tie (Step 2 of Figure 14A). One 
tip of a micro-forceps was then inserted into the artery for 10 seconds to dilate it, 
preparing it for cannulation. A 1.2G cannula (Solomon Scientific, TX, USA) was 
inserted into the femoral artery beyond the proximal tie (Step 3 of Figure 14A). The 
cannula was secured by tightening the proximal and distal ties (Step 4 of Figure 
14A). A pulsation within the cannula should be observed at this point as a sign of 
success. The MAP was read and recorded via the Physiomex® data recorder system.  
Finally, a MouseOX® pulse oximeter (Starr Lifesciences Corporation, Oakmont, PA) 
with mouse tail clip was used to detect, monitor and record oxygen saturation and 
heart rate. Brain death was induced as described above. Fluid support was provided 
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as outlined above. In some instances, kidneys from the BD mice were removed and 
transplanted into syngeneic recipients. 
 
 
Figure 13 Exposure of the femoral artery. A - Exposure of the femoral 
neurovascular bundle; B - Separating the artery from surround tissues and vessels. 
  
 B  A 
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Figure 14 Depiction of femoral artery cannulation. A - Steps to performing a 
successful femoral artery cannulation. Step 1 shows the ligation of the distal end of 
the femoral artery and retraction with suture of the proximal end to prevent 
bleeding when the artery is transversely slit open in step 2. Step 3 shows the 
cannulation of the femoral artery and step 4 shows the securing of the cannula 
within the artery; B - Overview of the setting when doing the procedure. 
 
2.3 Determination of preferred method of ureteric reconstruction for mouse 
kidney transplantation. 
Our research group has utilised two different methods for ureteric reconstruction 
during mouse kidney transplantation. Prior to commencing kidney transplantation 
from brain dead donors, we undertook a study with both retrospective and 
prospective arms, comparing the two methods. The results of this study are 
described in more detail in ‘Chapter 4: Determination of the optimum method of 
ureteric reconstruction for use in mouse renal transplantation’. Based on the 
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findings, we decided to use the ureteric implant method for all subsequent 
transplants. This method is described below. 
2.4 Renal Transplantation 
Syngeneic renal transplants were performed using male C57BL/6 mice as both 
donors and recipients. Some donors underwent brain death and maintenance for a 
period of either one or three hours prior to removal of the donor kidneys. In 
addition, some donors and recipients had been injected with an rAAV vector 
encoding esRAGE or a control protein (eGFP or human serum albumin) seven days 
prior to transplantation. 
2.4.1 Donor Procedure 
The left kidney of the BD donor was collected for transplantation. The donor 
procedure started with the shaving of the abdomen following application of 70% 
ethanol for skin sterilisation. A long midsaggital incision was then made from the 
xiphoid process to the pubis. A paperclip retractor was used to expose the left 
kidney. The left kidney and ureter were then mobilised from the surrounding 
tissues, and the ureter was cut distally, close to the bladder. The aorta and IVC 
together with the left renal artery and vein and surrounding vessels were then 
dissected and mobilized. A loose 5-0 silk tie was placed around the vascular bundle 
of infra-renal aorta and IVC. The SMA was then tied off with a 5-0 silk tie followed 
by the ligation of the supra-renal aorta with 5-0 silk. Once completed, the supra-
renal IVC was transected, followed by immediate perfusion distal to the loose tie 
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through the infra-renal aorta. 2ml of heparinised saline at 4oC was slowly injected 
using a 30 gauge needle connected to a syringe. After successful perfusion, the 
loose tie previously placed around the infra-renal aorta and IVC was tied firmly. The 
supra-renal aorta distal to the previously placed tie was then cut. The left kidney 
was mobilised by transecting the vascular bundle of aorta and IVC distal to the tie, 
see Figure 15. The donor kidney, with the aorta and IVC segment, was then stored 
in sterile saline at 4oC whilst preparing the recipient for transplantation. 
 
 
Figure 15 Steps to procurement of donor kidneys. The steps to harvesting the 
donor kidneys are outlined here (left). On the right hand side is what a successful 
procurement of the kidney should look like.  
  
Steps 1-7 of kidney harvesting:
1. Tying off SMA 4. Perfusion 7. Transection IVC & aorta bundle
2. Tying aorta 5. Tying IVC & aorta bundle
3. IVC transection 6. Aorta transection
1 2
3
4
5
6
7
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2.4.2 Recipient Transplant 
Anaesthesia of the recipient mouse was induced and then maintained using 1.5-2.0% 
of inhalational isoflurane evaporated with 0.3L/min of oxygen delivered to the 
mouse through a nose cone. After shaving and skin sterilisation, an abdominal 
midsaggital incision was made, as for the donor procedure. Paperclip retractors 
were used to expose the field around the left kidney. Gauze soaked in normal saline 
was used as a sponge to keep the bowel moist and retract it to the upper right side 
of the abdomen to expose the aorta, IVC and left kidney. 5-0 silk ties were placed 
around the left renal artery, vein and ureter. The left kidney was then removed, see 
Figure 16 below. The aorta and IVC were then mobilised from the left renal artery 
and vein down to the iliac bifurcation, the associated lumbar arteries and veins 
were divided. Two small vessel clamps were then placed on the aorta and IVC 
segment both distally and proximally. A vertical incision was made in the anterior 
wall of the aorta with microsurgical scissors to match the calibre of the donor aorta, 
see Figure 16 below. The donor kidney was then removed from the saline storage 
solution and placed at the recipient site, covered with a cold saline sponge. The 
donor aorta was anastomosed, end to side, to the recipient aorta using 10-0 
continuous micro-sutures.  A similar anastomosis was then made with the donor to 
recipient IVC, see Figure 17 below. The two vessel clamps were released to allow 
blood flow to the revascularised graft, see Figure 18 below. A small piece of Gel-
foam was placed around the anastomosis with cotton buds to control any bleeding. 
The kidney was placed to the left side of the abdomen and the ureter was 
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orientated to ensure there was no twisting or kinking. A 5-0 needle and silk suture 
(Ethicon) was used with the suture tied to the end of the ureter. The needle was 
then pulled through the recipient bladder from the back wall to the front wall, 
followed by the suture and attached ureter. Two to three stitches of 10-0 nylon 
(Ethicon) were applied to fix the adventitial tissue surrounding the ureter to the 
bladder where it entered at the back wall. Excess ureter was cut at the bladder front 
wall and after retraction of the ureter, the bladder defect was closed with one 10-0 
suture (Figure 19, below). The method for ureteric implantation described here has 
been developed in our research group, and differs from the previously published 
methods [171] in that it avoids the requirement to pull the ureter through the 
bladder with forceps. This modification results in less trauma to the bladder, allows 
easy manipulation and fixation of the ureter, and prevents the ureter from slipping 
out of the bladder following implantation.  Following ureteric anastomosis, the 
abdomen was washed and moistened with room temperature saline and the kidney 
graft and bowel returned to their anatomical positions. Abdominal closure was 
achieved using a 5-0 absorbable suture for muscle followed by skin. At the end of 
the recipient operation, the animal was injected with buprenorphine IM for 
analgesia and Ampicillin for infection prophylaxis, and then allowed to recover in a 
heated box. 
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Figure 16 Preparation of renal recipient for transplantation. The recipient left 
kidney had been removed and the aorta and IVC had been prepared for renal 
transplantation. 
 
 
Figure 17 Implantation of donor kidney into recipient. The anastomosis of the 
artery is done first followed by the anastomosis of the vein. 
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Figure 18 Depiction of successful renal transplantation. The appearance and colour 
of the kidney (right) upon successful transplantation. 
 
 
Figure 19 Steps involded in the ureteric implant method. A suture is tied to the 
end of the ureter and pulled through the bladded from the back (step 1). A few 
stitches are used to fix the adventitial tissue surrounding the ureter to the bladder 
where it entered at the back wall (step 2). Excess ureter was cut and allowed to 
shrink back into the bladder (step 3). And finally, a few stiches are used to close the 
front opening of the bladder (step 4).  
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2.5 Sample Harvesting 
2.5.1 Serum 
Whole blood was collected from the IVC with a 21G needle and syringe, then 
transferred into an eppendorf tube. The blood was allowed to clot at RT for 1 hour 
prior to centrifugation at 3,000rpm for 15 minutes. The upper clear layer (serum) 
was transferred to a new eppendorf and then spun for another 15 minutes at 
14,000rpm. The top layer (serum) was then transferred into separate eppendorf 
tubes in 50µL aliquots. 
2.5.2 Organs 
Heart, lungs, liver, kidneys, spleen and pancreas were collected into OCT for frozen 
sectioning, formalin for paraffin sectioning, and liquid nitrogen as snap frozen 
pieces for RNA extraction and analysis. The kidneys and spleen were cut 
transversely prior to embedding. For mice that had undergone kidney transplants, 
only the serum, kidneys (both native and transplanted) and spleen were harvested 
as described above. 
2.6 Cloning and subcloning of esRAGE cDNA 
A cDNA encoding human esRAGE was obtained in two different ways. Firstly, 
esRAGE was amplified from normal human lung explanted in the course of 
resecting a pulmonary tumour. Amplification primers were forward 
CACCATGGCAGCCGGAACAGCAGTTGGAGC and reverse 
GCGGATATCCTTGTTGACCATCCCCCCAG. PCR products were run on 1% agarose gel 
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to confirm that a band of expected size was amplified (see Figure 22 in Chapter 3), 
then sequenced using CACCATGGCAGCCGGAACAGCAGTTGGAGC. 
In parallel, a codon-optimised cDNA sequence for esRAGE had been ordered from 
GeneArt (Life Technologies, NY, USA). 5µg of the pMA plasmid containing this cDNA 
was resuspended into 50µL of ultrapure H2O and then transformed into SURE-2 
competent E. coli (Stratagene, CA, USA) and allowed to grow on agar plates. A few 
colonies from the plate were selected for Mini-preparation and colony PCR using 
Quick Mini-prep Kit (Invitrogen, CA, USA) to verify that plasmids contained the 
esRAGE cDNA.  Once the inserts were verified, a colony was selected for Maxi-
preparation. Plasmid DNA concentration was estimated by measuring absorbance 
at 260nm on a nanodrop spectrophotometer (Thermo Scientific, MA, USA). 
Restriction enzyme digestion NotI (New England Biolabs, MA, USA) and EcoRV (New 
England Biolabs, MA, USA) and agarose gel electrophoresis confirmed the presence 
of a band running at the expected size of 1113 base pairs (bp). The esRAGE insert 
was amplified from the maxi-prepped plasmid DNA using esRAGE-specific primers 
as above, then both the GeneArt sequence and the native sequence were TOPO 
cloned into pcDNA3.2 (Invitrogen, CA, USA), a mammalian expression vector. The 
pcDNA3.2 plasmids containing each of the esRAGE cDNAs were then transformed 
into one shot Top-10 E. coli. Correct sequencing was confirmed once again with 
Mini-preparation and PCR. Following this, expression of the esRAGE protein from 
these constructs was tested in vitro by transfecting the mammalian cell line 
HEK293D with the pcDNA 3.2-esRAGE plasmid, collecting the supernatant at 48 and 
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72 hours after transfection and quantitating esRAGE using the commercially-
available human esRAGE sandwich ELISA (B-Bridge International, CA, USA). The 
ELISA method is described below at ‘2.8.1 esRAGE ELISA’. Protein expression in vitro 
was slightly higher from the GeneArt than from the native construct, and so the 
codon-optimised GeneArt construct was used in all further experiments. 
2.7 Production and Packaging of an rAAV 2/8 vector encoding human esRAGE 
Packaging of recombinant rAAV 2/8 vectors requires that the packaging cell line 
HEK293D is triple-transfected with the following plasmids: pAM2AA (encoding the 
gene of interest and the inverted terminal repeats of the AAV serotype 2 genome) 
p5E18VD2/8 encoding the rep gene from AAV2 but the viral capsid protein from 
AAV serotype 8, and pXX6 (encoding adenoviral helper factors). 
 
 
 
 
Figure 20 Triple transfection with pAM2AA, pXX6 and p5E18VD2/8, yields 
rAAV2/8 virions after purification.   
 
  
 
I
T
I
T
ApoE/h
AAT
esRAGE WPRE, 
PolyA
p5 
promoter
Rep2 Cap8 
p5 
promoter
Adenovirus TF 
54 
 
 
 
To produce complementary sticky ends and ensure rapid directional ligation, the 
template expression vector pAM2AA-eGFP and PCR fragments of esRAGE were 
simultaneously digested with EcoRV and NotI to release esRAGE fragments as well 
as to linearize the pAM2AA-eGFP vector. 
The digested pAM2AA and esRAGE fragments were run on a 1% agrose gel and 
extracted using Wizard Gel Extraction Kit (Promega, WI, USA). These were the 
ligation products. The amount of PCR product used in the ligation was set at a 3:1 
vector: insert ratio, and the ligation was performed using Quick T4 DNA Ligase (New 
England Biolabs, MA, USA) in a 5µl reaction at 5 minutes room temperature. 
The products of the ligation were transformed into SURE-2 Supercompetent cells 
(Stratagene, CA, USA). The transformed cells were plated onto agar plates with 
ampicillin (100µg/mL) at 2 different concentrations of 20µL and 200µL. A resistant 
colony was randomly selected for Mini-preparation and colony PCR to verify 
sequence. Once verified, correct clones underwent Maxi-preparation and then 
sequence confirmation as described above in ‘2.6 Cloning and subcloning of esRAGE 
cDNA’.  
Once the sequence was verified, p5E18 and pXX6 were used along with pAM2AA-
esRAGE for packaging. HEK293D cells were cultured at 37oC in 5% CO2 with standard 
medium: DMEM supplemented with 10% fetal calf serum (FCS). These cells were 
seeded into 40x10cm2 tissue dishes. The following day, the medium was refreshed 
in the morning and a triple transfection using calcium phosphate was performed 3 
hours later. At 16 hours post-transfection, standard medium was replaced with 
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DMEM + 2% FCS. Cells were then harvested 48 hours post-transfection and 
immediately stored at -80oC.  
Virions were separated from cell lysate using a cesium chloride gradient purification, 
and then concentrated. Viral quantification was performed using quantitative real 
time PCR and aliquotted at 5x1011 viral genome copies for use. 
2.8 ELISAs and ELISA-based assays 
2.8.1 esRAGE ELISA 
The esRAGE Human ELISA Kit (Cat # 1009-1, B-Bridge International) was used for 
quantitative determination of mouse esRAGE concentrations in tissue culture 
supernatant and in mouse serum.  
The kit utilises the sandwich ELISA format. A microplate is pre-coated with the 
capture antibody, which is specific for the unique 20 amino acids at the C-terminus 
of esRAGE. The assay was carried out according to the manufacturer’s protocol. 
20µl of sample was added to each well with 100µl of esRAGE antibody HRP 
conjugated and incubated for a 20 hour period. After incubation plates were 
washed in PBST with BSA (provided in kit). Tetramethylbenzidine and hydrogen 
peroxide were added as a substrate for colour development and reaction was 
stopped after 30 minutes. Absorbance was measured at 450nm on a FLUOstar 
Omega plate reader (BMG Labtech, Germany). This assay is intended for detection 
of human esRAGE in the physiological range in human subjects. Overexpression of 
human esRAGE in mouse liver resulted in serum levels that were sometimes over 
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5,000-fold greater than the upper limit of the dynamic range of the assay 
(0.05ng/ml to 3.2ng/ml). For this reason, tissue culture supernatants and sera were 
diluted in kit diluent between 1:2500 and 1:62,500 prior to assay. 
2.8.2 Lipocalin-2 / NGAL ELISA 
Quantikine® mouse lipocalin-2/NGAL immunoassay (Cat # MLCN20, R&D Systems 
Inc.) was used for quantitative determination of mouse lipocalin-2/NGAL 
concentrations in mouse serum.  
According to the user manual: “This assay employs the quantitative sandwich 
enzyme immunoassay technique. A monoclonal antibody specific for mouse 
Lipocalin-2 had been pre-coated onto a microplate. Standards, control, and samples 
are pipetted into the wells and any mouse Lipocalin-2 present is bound by the 
immobilized antibody. After washing away any unbound substances, an enzyme-
linked monoclonal antibody specific for mouse Lipocalin-2 was added to the wells. 
Following a wash to remove any unbound antibody-enzyme reagent, a substrate 
solution is added to the wells. The enzyme reaction yields a blue product that turns 
yellow when the stop solution is added. The intensity of the colour measured is in 
proportion to the amount of mouse Lipocalin-2 bound in the initial step. The 
sample values are then read off the standard curve” [172]. The assays were carried 
out according to the manufacturer’s protocol.  
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The only aspects not determined by these protocols are the serum dilutions. The 
following dilutions were prepared: 
Dilution1: 1:100,  2µl serum + 198µl calibrator diluent 
Dilution2: 1:1000, 10µl Dilution1 + 90µl   calibrator  diluent 
Dilution3: 1:10000, 10µl Dilution2 + 90µl   calibrator  diluent 
Dilution4:  1:100000,  10µl Dilution3  + 90µl   calibrator  diluent 
2.8.3 S100B ELISA 
Enzyme-linked Immunosorbent Assay Kit for S100 Calcium Binding Protein B (S100B) 
(Cat # E90567Mu, Uscn Life Science Inc.) was used for quantitative determination of 
mouse S100B concentrations in mouse serum. The assay was carried out according 
to the manufacturer’s protocol. 100µl of sample was incubated for 2 hours and 
then 100µl of detection antibody was added. Plate was washed and 
tetramethylbenzidine and hydrogen peroxide were added as a substrate for colour 
development and reaction was stopped after 30 minutes. Absorbance was 
measured at 450nm on a FLUOstar Omega plate reader (BMG Labtech, Germany). 
Samples were diluted with 0.02M PBS at 1:2 and 1:10 for values to lie within the 
detection limits of 23.5pg/ml up to 1500pg/ml.  
2.8.4 Proinflammatory Cytokines (Multiplex) 
MILLIPLEX® xMAP Mouse Cytokine / Chemokine magnetic bead panel kit (Cat # 
MCYTOMAG-70K, MilliporeTM was used to simultaneously quantify the following 25 
murine cytokines and chemokines: G-CSF, GM-CSF, IFNγ, IL-1α, IL-1β, IL-2, IL-4, IL-5, 
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IL-6, IL-7, IL-9 IL-10, IL-12, IL-12, IL-13, IL-15, IL-17, IP-10, KC, MCP-1, MIP-1α, MIP-
1β, MIP-2, RANTES and TNFα.  
The MILLIPLEX® xMAP is based on the Luminex® xMAP® technology. According o 
information from the manufacturer “This technology uses (proprietary) techniques 
to internally colour code microspheres with two fluorescent dyes. One hundred 
distinctly coloured bead sets are able to be created, each of which is coated with a 
specific capture antibody. After an analyte from a test sample is captured by the 
bead, a biotinylated detection antibody is introduced. The reaction mixture is then 
incubated with Streptavidin-PE conjugate, the reporter molecule, to complete the 
reaction on the surface of each microsphere. The microspheres are allowed to pass 
rapidly through a laser which excites the internal dyes marking the microsphere set. 
A second laser excites PE, the fluorescent dye on the reporter molecule. Finally, 
high-speed digital-signal processors identify each individual microsphere and 
quantify the result of its bioassay based on fluorescent reporter signals” (adapted 
from the MILLIPLEX® MAP user manual [173]).  
The assays were carried out on mouse sera according to the manufacturer’s 
protocols. The only aspect not predetermined by these protocols are the serum 
dilutions. The samples were diluted 1:2 by adding 13µL of the mouse’s serum to 
13µL of assay buffer. Some samples were also diluted 1:4 by adding 7µl of serum 
with 21µl of serum matrix.  
Samples were incubated at 4 oC with antibody-coated beads overnight. The 
following day, 25µl of detection antibody was added and the plate was further 
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incubated at RT for 1 hour. Then a detection reagent was added to each well and 
incubated at RT for 30 minutes. The plate was then washed and beads resuspended 
in sheath fluid and run on the Luminex 200 (Millipore). 
2.9 Frozen Sections for Staining and Immunohistochemistry 
6 µm sections were cut from frozen OCT blocks using a Cryostat (Shandon 
Cryotome E, Thermo Scientific, MA, USA). Sections were guided onto pre-coated 
slides (SuperFrost®, MENZEL-GLÄSER, Berlin, Germany), then allowed to air dry for 
1 hour at RT followed by an acetone fix of 8 minutes at RT. Once fixed, the slides 
were allowed to air dry at RT for 10 minutes and then either wrapped in foil and 
stored at -80oC or stained immediately. If the slides were stored at -80oC prior to 
staining, the slides were allowed to thaw (wrapped in foil) at RT for at least 15 
minutes and then unwrapped and allowed to air dry for 30 minutes at RT. A wax 
pen (Dako, Denmark) was used to draw around the sections to help retain the 
solutions on the sections during incubations. The amount of solution added to 
sections varied from 50-100µL depending on the size of the section. During the 
staining process, slides were kept moist in a humidified chamber until the final step. 
Staining was carried out at room temperature unless otherwise indicated. 
2.9.1 Staining for Macrophages 
2.9.1a CD 68 
Slides were initially washed with 3 changes of PBS buffer for 3 minutes each and 
then incubated in 0.06% H2O2/PBS buffer for 10 minutes to block endogenous 
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peroxidase activity. The slides were washed again in 3 changes of PBS buffer for 3 
minutes each and then incubated with avidin solution (Dako, Denmark) for 10 
minutes to block endogenous biotin. The slides were then briefly rinsed in PBS 
buffer and incubated with biotin solution (Dako, Denmark) for 10 minutes to block 
residual avidin. The slides were rinsed in PBS buffer and then the sections were 
blocked in 20% normal horse serum/PBS buffer for 20 minutes.  
The primary antibody (rat anti-mouse-CD68, FA-11, Cat # MCA1957, AbD Serotec, 
North Carolina, USA) at a dilution of 1:400 in 1% normal horse serum/PBS buffer 
was added to the sections and allowed to incubate at RT for 1 hour. Following the 
incubation, the slides were once again washed 3 times in PBS buffer for 3 minutes 
each. The secondary antibody (biotinylated goat anti-rat, polyclonal, Cat # 559286, 
BD Pharmingen, CA, USA) at a dilution of 1:200 in 1% normal horse serum/PBS 
buffer) was then added and incubated at RT for 1 hour.  
The slides were washed in 3 changes of PBS buffer for 3 minutes each followed by 
the addition of a detection agent to the sections for 30 minutes. The detection 
agent was prepared 30 minutes before use by mixing 1:100 reagent A and 1:100 
reagent B (Vector Laboratories, Peroxidase standard, Cat # PK 4000) in 1% normal 
horse serum/PBS buffer. After this incubation, the slides were washed 3 times for 3 
minutes each in PBS buffer followed by a quick rinse in water.  
Chromogen solution was then added to each section for 2-3 minutes. The 
chromogen solution was prepared by adding one drop of DAB (Diaminobenzidine) 
per 1 ml of DAB substrate buffer (Dako North America Inc). The slides were then 
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washed 3 times for 3 minutes in distilled water. The slides were counterstained and 
coverslipped as described below under ‘2.11 Counterstaining and coverslipping’. 
2.9.1b F 4/80 
Initially, the primary antibody (anti-mouse F4/80 antigen FITC, BM8, Cat # 11-4801-
82, eBioscience, CA, USA) at a dilution of 1:400 in IP diluent was added to the 
sections and allowed to incubate for 30 minutes at RT. The slides were then washed 
in TBST twice for 5 minutes each. The secondary antibody (rabbit anti-FITC-HRP, 
polyclonal, Cat # 18-783-77622, GenWay, CA, USA) at a dilution of 1:200 in IP 
diluent with 20% heat-inactivated normal mouse serum was added to the sections 
and incubated for 30 minutes at RT. The slides were washed again in TBST twice for 
5 minutes each followed by the addition of the chromogen solution for 6 minutes at 
RT. The chromogen solution was prepared by adding one drop of DAB 
(Diaminobenzidine)(Dako North America Inc) per 1 ml of DAB substrate buffer 
(Dako North America Inc) with 15µl of 18% sodium azide per 1ml of the solution. 
The slides were then washed 3 times for 3 minutes in water, and counterstained as 
described below. 
2.9.2 Staining for regulatory T cells (FoxP3) 
Slides were initially rinsed briefly in TBST and then incubated in cold 0.1% v/v 
Triton-X-100 in 0.1% w/v Na citrate for 2 minutes on ice. The slides were then 
washed in TBST for 5 minutes twice and the sections were blocked with IP diluent 
containing 20% normal mouse serum (NMS) for 20 minutes. A tapping/shaking 
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motion was used at the end of the block to remove the blocking solution and the 
primary antibody (anti-mouse/rat FoxP3 FITC, FJK-16s, Cat # 11-5773-82, 
eBioscience, CA, USA) diluted in IP diluents at a ratio of 1:50 was added and allowed 
to sit for 45 minutes. The isotype control used was rat IgG2a diluted in IP diluent at 
a ratio of 1:50. The samples were washed twice in TBST for 5 minutes each and 
then the secondary antibody (rabbit anti-FITC-HRP, polyclonal, Cat # 18-783-77622, 
GenWay, CA, USA) diluted in IP diluent with 20% heat inactivated NMS at a ratio of 
1:200 was added for 30 minutes.  
The samples were washed twice in TBST for 5 minutes each and DAB solution with 
the addition of 18% sodium azide was applied to the sections for 6 minutes. Once 
colour development was complete, slides were transferred immediately into tap 
water. The slides were rinsed in 3 changes of water and then allowed to either air 
dry overnight at RT or counterstained immediately while the slides were still wet.  
2.10 Paraffin Sections for Staining and Immunohistochemistry 
For determination of morphology by Haematoxylin and Eosin (H&E) and Periodic 
Acid Schiff (PAS) stains, and for some immunohistochemical staining, formalin-fixed 
tissues were embedded in paraffin wax and then cut into thin slices. Three steps 
were used in this process, dehydration, clearing and paraffin wax infiltration. The 
dehydration process is used to replace the water in tissues with alcohol. 
Dehydration facilitates wax infiltration and sectioning. The dehydration step was 
performed by placing the tissue into graded alcohols 70%, 80%, 95%, 100% and 100% 
for two hours each. The clearing process then removes the alcohol from the tissue 
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and replaces it with an intermediate solvent that is miscible with paraffin wax. This 
was done by placing the dehydrated tissue in two changes of xylene for 1.5 hours 
each. The final step was to replace the clearing agent with molten paraffin wax. The 
wax infiltrates the specimen to fill out all cavities in the tissue and to support the 
delicate structure of the tissue against the shearing forces of sectioning. This 
process required four changes of molten wax to ensure complete removal of the 
clearing agent, each step lasting one hour.  
A microtome sectioning instrument was used to obtain 5µm sections of the kidney 
specimens which were then mounted onto microscope slides. After cutting, the 
sections were floated onto a 42°C water bath and then picked up and placed onto a 
pre-coated slide (SuperFrost®, MENZEL-GLÄSER, Berlin, Germany). The slides were 
then placed in a 45°C oven overnight to fix the specimens onto the slides. The first 
step in each staining process was to deparaffinise the sections, this was done by 
rehydrating the slides by placing them in two changes of xylene for 15 minutes each, 
followed by two changes of 100% alcohol, two changes of 95% alcohol, one change 
of 70% alcohol and then washing in water (two minutes each). All incubations were 
carried out at ambient temperature using room temperature reagents unless 
otherwise stated. 
2.10.1 Haematoxylin and Eosin (H&E) staining 
The slides were placed in Harris’s haematoxylin for two minutes and then washed in 
water to remove excess haematoxylin. To differentiate the nuclei and cytoplasm, 
excess stain is removed by quickly dipping the slides in acid alcohol ten times and 
64 
 
 
 
then washing in water again. The slides were then placed in Scott’s blueing solution 
for 30 seconds and then washed in water once again. The slides were examined 
under a microscope to assess whether the nuclei were clearly stained and that the 
cytoplasm was not. If the staining was not adequate then the slides would have to 
be passed through the same steps from the acid alcohol once more.   
If the staining of the nuclei was acceptable, the slides would be placed in 70% 
ethanol for 30 seconds. This was followed by staining the slides in two changes of 
eosin, 40 seconds each. Slides were then dehydrated and coverslipped as described 
below. 
2.10.2 Periodic Acid Schiff (PAS) Staining 
After deparaffinisation and hydration, the sections were placed into 1% periodic 
acid solution for 15 minutes followed by a brief wash in tap water. The sections 
were then rinsed in distilled water for 5 minutes followed by a 30 minute 
incubation in Schiff’s solution. The sections were washed in tap water for 15 
minutes and then counterstained, dehydrated and coverslipped as outlined below. 
2.10.3 Staining for Neutrophils 
The initial step in this staining process was antigen retrieval. This process is 
performed to expose epitopes which have become masked by the tissue fixation 
process. We did this by placing the slides in a plastic specimen container containing 
a citrate buffer (10mM trisodium citrate dehydrate pH 6.0). The container was then 
placed on top of a heat shield within a pressure cooker pan containing 500ml of 
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water. The pressure cooker used was a Digital decloaking chamber (BioCare 
Medical) and the settings used for the pressure cooker were as follows: no delayed 
start, preheat for 30 seconds at 80°C, auto-continue function on, P1 125°C, P2 fan 
on 95°C, P2 fan off 90°C.  
Once the specimens had cooled down to room temperature they were washed in 
TBST buffer three times for three minutes each. After the washing, a wax outline 
was drawn around each of the sections with a Dako pen and then 80 µL of blocking 
solution was placed on the sections for 20 minutes. The blocking solution 
comprised 20% normal goat serum in a diluent TBST buffer.  
After the blocking step the sections were incubated with the primary antibody for 
one hour. The primary antibody used was a Rat Anti Mouse Ly-6B.2 Alloantigen 
(AbD Serotec), this was diluted 1:100 in 1% normal goats serum/TBST diluent. Two 
control stains were used for this step, the negative control stain used was 1% NGS 
in TBST diluent, the isotype control (no specificity for neutrophils) used was FITC 
Rat IgG2a k Isotype control (BD Bioscience) 1:50 in 1% normal goat serum/TBST 
diluent. The specimens were then washed three times for three minutes in TBST 
wash buffer.  
Following this, the slides were incubated in 3% H2O2/methanol for 5 minutes. This 
step was done to block any endogenous peroxidase activity. The slides were then 
washed again three times for three minutes in TBST wash buffer. All sections, 
including those stained with the control antibodies, were then incubated with the 
secondary antibody. The secondary antibody used was biotinylated goat anti-rat 
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(BD Bioscience) diluted 1:150 with 1% normal goats serum/TBST diluent. After 
incubation the slides were washed three times in TBST wash buffer for three 
minutes each. Detection was performed using the Vectastain ABC system as for 
CD68 above. The slides were then counterstained, dehydrated and coverslipped as 
below. 
2.10.4 Staining for Proliferating Cell Nuclear Antigen (PCNA) 
The staining for PCNA was similar to that of neutrophils. The only differences were 
that, for PCNA, slides were place in a plastic specimen container containing Tris 
buffer (pH 9) for antigen retrieval instead and that PCNA utilised different primary 
and secondary antibodies at different concentrations. For PCNA staining, the 
primary antibody (rabbit anti-PCNA, polyclonal, Cat # ab2426, abcam, England) was 
added at a dilution of 1:500 and the secondary antibody (biotinylated goat anti-
rabbit, polyclonal, Cat # E0432, Dako, Denmark) was added at a dilution of 1:300.  
2.11 Counterstaining and coverslipping 
Both immunohistochemistry from frozen sections and paraffin sections were 
counterstained using the same process. The slides were counterstained in Harris’ 
haematoxylin for 5-10 seconds and then washed in water to remove excess staining. 
To differentiate the nuclei and cytoplasm staining, excess stain was removed by 
dipping slides in acid alcohol 1-3 times and then washing in water. The slides were 
then placed in Scott’s blueing solution for 30 seconds and washed in water once 
more. The slides were examined under a microscope to assess whether the nuclei 
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were clearly stained and that the cytoplasm was not. If the staining was not 
adequate then the slides would have to undergo the above steps again.   
The next step in the process was to dehydrate the slides. This was done by placing 
the slides in graded alcohols 70%, 95%, 95%, 100%, 100% for two minutes each and 
then finally in two changes of histolene/xylene for two minutes each. 
The final step in the process is to coverslip the slides. This is done by placing DPX 
(dibutylphthalate polystyrene xylene) on microscope slide coverslips and then 
placing the slides on top of this solution. Air bubbles were then removed from 
between the coverslip and the slide with a probe and the slides were left to dry.  
2.12 RT-PCR 
2.12.1 RNA Extraction 
RNA was extracted with an RNAqueous-MiniTM kit (Ambion, Texas, USA) following a 
modified protocol. Lab coat, face mask and gloves were worn throughout the 
procedure. All steps were carried out on ice unless mentioned otherwise. 4 Falcon 
tubes of 50ml of triple distilled water (TDW) at RT were used to wash the 
homogeniser (Polytron@ PT2100) initially and in between samples, 700µL of lysing 
buffer (RNAqueous-MiniTM kit, Ambion, Texas, USA) was placed into a RNAse-free 
2ml Eppendorf tube on ice for each sample. A frozen tissue specimen of approx 3m3 
was placed inside a tube with the lysis buffer and homogenized with the 
homogeniser. Repeated aspiration and expulsion with a 26G gauge needle and 
syringe was used to shear DNA and decrease the viscosity of the lysate.  
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70µL of 2M sodium acetate (Sigma) was then added to the tube and mixed briefly, 
followed by the addition of 700µL of RNA grade phenol solution (Sigma). The tube 
was then vortexed thoroughly for 30 seconds and left on ice for 5 minutes to settle. 
140μL of chloroform (BDH AnalaR, Kilsyth, Australia) / isoamyl alcohol (BDH AnalaR) 
was then added, vortexed thoroughly for 30 seconds, and allowed to sit on ice for 
15 minutes. The tube was then centrifuged at 11,000rpm at 4oC for 45 minutes 
using a centrifuge (5415R, Eppendorf International, Germany).  
Once the centrifugation was completed, the aqueous (upper) phase of the solution 
was transferred into a new 2mL Eppendorf tube, taking care not to transfer any of 
the interphase (middle) or phenol (lower) phase as they contain contaminating DNA 
and protein.  
800µL of 65% ethanol (RNAqueous-MiniTM kit, Ambion, Texas, USA) was added to 
the removed aqueous phase. This was then purified on an RNA affinity column 
(RNAqueous-MiniTM kit, Ambion, Texas, USA) following the manufacturer’s protocol. 
To the 180µL of eluted RNA, 2µL of glycogen, 12µL of 7.5M ammonium acetate and 
390uL of 100% ethanol were added and left to precipitate overnight at -20oC before 
being centrifuged at 11,000rpm at 4oC for 45 minutes. 
The supernatant was removed carefully with gentle pipetting as to not disturb the 
pellet. The RNA pellet was then washed with 1.5mL of 70% ethanol and centrifuged 
at 11,000rpm at 4oC for 10 minutes. The supernatant was once again removed 
carefully, as above. The pellet was then allowed to air-dry at RT for 10 minutes 
before dissolved and mixed thoroughly in 30μL of DEPC-water. 
69 
 
 
 
Absorbance of 1µL of the extracted RNA in DEPC-water was measured, using a 
Nanodrop Spectrophotometer (ND-1000, Thermo Scientific, MA, USA) to determine 
its concentration. The RNA was diluted down to 0.2µg/µL, and stored in liquid 
nitrogen. 
2.12.2 Analysis of RNA quality using the Agilent Bioanalyser 
Agilent RNA 6000 Nano Kit (Cat # 5067-1511, Agilent Technologies) was used to 
analyse the integrity of the extracted RNA. The analysis was carried out according 
to the manufacturer’s protocol. The instrument generates an absorbance spectrum 
(Figure 21 below) which is used to calculate the RNA integrity number (RIN). All 
samples had a RIN greater than 7.5, providing evidence of high quality RNA without 
degradation. 
 
 
Figure 21 Absorbance spectrum generated to calculate RIN. This an example of the 
spectrum used to calculate RIN. 
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2.12.3 cDNA Synthesis 
All steps were carried out on ice unless mentioned otherwise. 1µg of RNA (5µL of 
the stored product) was made up to 10µL with (5µL of) DEPC-water in a 0.2mL tube. 
3µL of Oligo dT was added to the sample and then mixed briefly before being 
heated for 5 minutes at 70oC. The sample was then spun briefly again and cooled on 
ice. To the sample, 4µL of 5x reaction buffer, 2µL 0.1M DTT and 1µL of 10mM dNTP 
were added. After the additions, the sample was mixed by pipetting up and down 
and then heated for 2 minutes at 50oC. 1µL of Superscript III (Invitrogen, CA, USA) 
enzyme was added before heating for 60 minutes at 50oC followed by 15 minutes at 
70oC. The final product (cDNA) was then diluted 1:5 with 80µL of DEPC-water and 
aliquotted in 4µL volumes into PCR trays. Caps were placed tightly over the wells 
and the trays were stored at -80oC until amplification. 
2.12.4 Analysis of Genes / PCR 
A master mix was prepared for each reaction. The master mix comprised 10μl of 2x 
Universal buffer (SensiMix, BIOLINE, USA), 0.2μl of 100x Primers (FOR+REV) (30μM), 
0.2μl of 100x Probe (20μM), and 5.6μl of TDW making up a total volume of 16μl. 
The master mix was mixed thoroughly and 16μl of the master mix was placed into 
each of the stored cDNA wells. The wells were capped and centrifuged for 1 minute 
at 1,000rpm at RT temperature in a centrifuge (Allegra X-12R, Beckman Coulter, 
USA) and then the plate was run on the LightCycler® 480 (Roche Diagnostics, 
Indiana, USA).  
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The Primers and Probes used were either ordered as a whole product from Applied 
Biosystems or individually designed using Primer Express and purchased from Sigma. 
The genes purchased as a completed product from Applied Biosystems were 
CXCL10 (Mm00445235), IL10 (Mm00439616), TGF-β (Mm00441724), IL6 
(Mm00446190), HSP2 (Mm00434069), TNF-α (Mm00443258) and TLR4 
(Mm00445274). For a list of the genes we designed and ordered from Sigma, refer 
to Table 1 below. 
Table 1 Designed sequences of Primers and Probes for genes of interest. The 
sequences for the genes of interest were designed using Primer Express and then 
purchased from Sigma. 
Genes Forward Reverse Probe 
GAPDH TGCACCACCAACTGCTTAG
C 
GGCATGGACTGTGGTCATG
AG 
CCTGGCCAAGGTCATCCATGAC
AACTT 
KC TTGGTTCAGAAAATTGTCC
AAAAG 
CAGGTGCCATCAGAGCAGT
CT 
TGCTAAAAGGTGTCCCCAAGTA
ACGGAGAAAG 
MCP1 GAGCATCCACGTGTTGGC
T 
TGGTGAATGAGTAGCAGCA
GGT 
AGCCAGATGCAGTTAACGCCCC
ACT 
MIP2 GCCCCCAGGACCCCA CTTTTTGACCGCCCTTGAGA TGCGCCCAGACAGAAGTCATA
GCCA 
CCL17 GGATGCCATCGTGTTTCTG CCAATCTGATGGCCTTCTTC TCCAGGGCAAGCTCATCTGTGC 
CCL22 GGAGTTCTTCTGGACCTCA
AAATC 
TCTCGGTTCTTGACGGTTAT
CA 
CAACGCCAGGCTTGCGGCA 
IL1β GCACACCCACCCTGCAG AACCGCTTTTCCATCTTCTTC
TT 
TGGAGAGTGTGGATCCCAAGC
AATACCC 
RAGE GGACCCTTAGCTGGCACTT
AGA 
GAGTCCCGTCTCAGGGTGTC
T 
ATTCCCGATGGCAAAGAAACA
CTCGTG 
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2.13 Statistical Analysis 
Different methods of statistical analysis were used in different chapters of the 
thesis. 
2.13.1 Chapter 3 
In Chapter 3, one-way ANOVA, followed by a post-hoc T-test with Bonferroni 
correction was used.  Results were presented as mean ± SEM. 
2.13.2 Chapter 4 
Here, comparison of complications (listed in Table 2) was performed using Fisher’s 
exact test. The survival analysis utilized the log-rank (Mantel-Cox) test. 
2.13.3 Chapters 5 and 6 
In Chapters 5 and 6, where distribution of data is parametric, it is displayed as mean 
± SEM. Where data appears to be non-parametric, it is displayed as individual data 
points with the median indicated.  
Comparison of multiple groups of parametric data was performed using one-way 
ANOVA, followed by a post-hoc T-test with Bonferroni correction. Pairwise 
comparisons of cell counts at a single time point (Figures 50 and 51) were 
undertaken using Student’s T-test. 
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CHAPTER 3: CLONING AND EXPRESSION OF esRAGE 
AND CONTROL CONSTRUCTS 
3.1 Creation and Amplification of rAAV esRAGE 
esRAGE was amplified from resected lung tissue, and agarose gel electrophoresis of 
the PCR products yielded a band of expected size (Figure 22 below).  
 
 
Figure 22 Amplification of esRAGE from human lung tissues. Primers specific for 
esRAGE amplified a PCR product of the expected size 1113 base pairs (bp) from 
resected human lung tissue. The position of the 1031bp fragment of the DNA ladder 
is indicated. 
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The nucleotide sequence was subsequently confirmed to be identical with that of 
the NCBI reference sequence for esRAGE (accession number AB061668). In parallel, 
a codon-optimised cDNA sequence for esRAGE was designed by GeneART (Life 
Technologies, NY, USA), using a proprietary algorithm. Codon optimisation is a 
process which exploits the redundancy of the genetic code to replace certain 
nucleotides with others which will not result in a change to the amino acid 
sequence of the translated protein product, but will create a more favourable 
secondary structure for high-level expression of the transgene product. The 
chromatogram and sequence is shown in Figure 23. 
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Figure 23 Codon-optimised nucleotide sequence of esRAGE designed by GeneART. 
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To verify that both esRAGE constructs would yield the correct secreted protein 
product, the native and codon-optimised GeneArt sequences were each subcloned 
into the mammalian expression vector pcDNA 3.2 TOPO as described in ‘Chapter 2’. 
HEK293D cells were transfected with this construct using Lipofectamine (Life 
Technologies, USA), and the supernatants collected at 48 and 72 hours post-
transfection. Concentration of esRAGE in supernatant was estimated using the B-
Bridge esRAGE ELISA kit. High levels of secreted esRAGE were detected in the 
culture supernatants of HEK293D cells transfected with plasmids containing either 
native or codon-optimised constructs (Figure 24). Expression appeared slightly 
stronger from the codon-optimised construct, and this was used for packaging into 
rAAV2/8 and all subsequent experiments. 
esRAGE was packaged into an rAAV2/8 vector as described in ‘Chapter 2’. A 
schematic diagram of the vector genome is shown below (Figure 25). 
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Figure 24 ELISA plate showing expression of esRAGE from both constructs (yellow 
wells). Wells 1-8 of rows D and F represent dilution series of TCS for cells 
transfected with codon-optimised (D) and  native (F) constructs. Expression was 
stronger from the codon-optimised construct. 
 
 
Figure 25 Schematic representation of esRAGE expression cassette. esRAGE is 
packaged into rAAV2/8. The inverted terminal repeats are the only elements 
remaining from wild-type AAV2. An ApoE/hAAT promoter/enhancer confers 
hepatocyte specificity. 
 
ITR ITR ApoE/hAAT esRAGE WPRE/PolyA 
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3.2 in-vivo expression of esRAGE  
Following the packaging of rAAV-esRAGE, we performed a dose-response 
experiment to determine the most appropriate vector dose. Male C57BL/6 mice 
aged 8-10 weeks received doses of rAAV-esRAGE of 1x1010, 5x1010, 1x1011, and 
5x1011 vector genomes (VG) via intraperitoneal injection (IP). The concentration of 
esRAGE was then measured in the serum of the injected mice at 10 days post-
injection. Systemic expression of esRAGE was dose-dependent, and the dose of 
5x1011 VG resulted in the highest esRAGE serum concentration (Figure 26). This 
vector dose did not result in liver inflammation as measured by serum ALT 
concentration or the presence of an inflammatory infiltrate upon H and E staining 
of the liver (Figure 27 A and B), and this dose was therefore chosen for use in later 
experiments.  
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Figure 26 Dose-response curve for rAAV-esRAGE. Mice were injected IP with 
esRAGE at doses ranging from 1x1010 to 5x1011 VG. Levels of esRAGE measured in 
serum by ELISA were dose-dependent and many thousand-fold greater than 
physiological concentration in humans (0.1-1 ng/mL). n=4-6 in each group. 
 
         
Figure 27 Administration of rAAV-esRAGE does not result in liver inflammation. 
Neither serum ALT levels (A) nor the appearances of liver on H and E staining (n=4-6 
in each group) (B) suggested liver inflammation with the highest dose of 5 x 1011 VG 
rAAV-esRAGE. 
B A 
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We next conducted a time-course experiment using 5x1011 VG intraperitoneally (IP) 
to determine the kinetics of rAAV2/8-mediated esRAGE expression. Murine esRAGE 
is undetectable in serum, and physiological concentrations of esRAGE in humans 
are in the range 0.1-1 ng/mL. By d2 following IP injection, levels around 5000-fold 
greater than physiological concentrations in humans had already been achieved. 
esRAGE levels continued to increase until d42 post-injection, then started to decline. 
Nonetheless, durable high-level expression was demonstrable throughout 100 days 
after injection. For practical reasons, it was determined that sufficient levels of 
esRAGE for our experimental purposes were reached by 7 days after IP injection. 
Procedures of brain-death induction and renal transplantation were therefore 
performed 7 days post-inoculation. 
 
 
Figure 28 Kinetics of expression for rAAV-esRAGE injected intraperitoneally (IP) at 
5x1011 VG. Serum esRAGE expression was already substantial by d2, and reached a 
peak at day 42 followed by a slow decline. n=4-6 in each group. 
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Finally, to verify our assumption that esRAGE secreted by the liver would be 
distributed throughout the body, and would appear in high concentration within 
transplantable organs, we collected liver, spleen, kidney and heart from two 
C57BL/6 mice at 5 days following IP injection with 5x1011 VG rAAV-esRAGE, and 
measured the concentration of esRAGE per gram of total protein in tissue lysates. 
Not surprisingly, the highest levels were detected in liver, where esRAGE is 
produced, followed by kidney where esRAGE is reabsorbed from the urine. Spleen 
and heart contained lower, but still substantial levels of esRAGE (Figure 29). No 
human esRAGE was detected in organs from control C57BL/6 mice.  
 
 
 
 
 
 
Figure 29 Levels of esRAGE in various organs. Concentrations of esRAGE in relation 
to total protein in tissue lysates were greatest for liver and kidney, and less, though 
still substantial for spleen and heart. No human esRAGE was detected in organs 
from control C57BL/6 mice. n=4-6 in each group. 
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3.3 Control vectors 
Two control vectors were used in subsequent experiments. A vector encoding 
Human serum Albumin was produced by PhD student Miriam Habib using albumin 
cloned from explanted human liver. Vector production and packaging were as 
outlined here for esRAGE, and a dose of 5x1011 VG yielded a concentration of 
human albumin of 90µg/mL. An rAAV vector encoding green fluorescent protein 
(eGFP) was the generous gift of Professor Ian Alexander. We performed a 
timecourse experiment to determine kinetics of expression by injecting the vector 
at a concentration of 5x1011 VG IP, then detecting green fluorescence of 
hepatocytes in two ways. Macroscopically, we used a fluorescence 
stereomicroscope (M165FC, Leica, Germany) with illumination at 395-455nm and 
an FITC filter to photograph the liver and surrounding tissues at days 0, 2, 5, 7, 10, 
21, 42 and 100. Specimens were also collected into OCT for sectioning and 
fluorescence microscopy.  
Macroscopic images obtained at each sampling time are shown in Figure 30 below. 
No fluorescence was observed on day 0. From day 2 onwards, liver fluorescence 
was detected, reaching peak intensity between days 21 and 42, with a modest 
decline by day 100. No fluorescence of other organs was detected. 
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Figure 30 Kinetics of expression of control vector rAAV-GFP. The left panel for 
each sampling time shows the abdomen illuminated with white light at the same 
time as blue light of 395-455nm. The right panel shows liver fluorescence alone. 
Strong liver fluorescence was detectable from d5 to d100 post-injection. 
Fluorescence of other abdominal organs was not detected. 
Day 0 Day 2 
Day 5 Day 7 
Day 10 Day 21 
Day 42 Day 100 
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CHAPTER 4:  DETERMINATION OF THE OPTIMUM METHOD OF 
URETERIC RECONSTRUCTION FOR USE IN MOUSE RENAL 
TRANSPLANTATION. 
4.1 Study Rationale 
Our research group has utilised two different methods for ureteric reconstruction 
during mouse kidney transplantation. Prior to commencing kidney transplantation 
from brain dead donors, we undertook a study with both retrospective and 
prospective arms, comparing the two methods. The methods are bladder 
anastomosis using a bladder patch, and ureteric implantation into the bladder. This 
second method is a refinement of previously published implant procedures.  
For the retrospective analysis, there were a total of 62 cases in which the bladder 
patch method was used and 101 cases where the implant method was used. Animal 
survival, and in cases of mortality, post-mortem findings are summarized in Table 2 
and Figure 31. For the patch method, 13 out of 62 animals died or were euthanized 
within 3 post operative days with a success rate of 79%. Using the implant method, 
14 out of 101 animals died or were euthanized within 3 post operative days with a 
success rate of 86.1%, which was not significantly different compared to that of the 
patch method (p=0.28). The reasons for early animal death included vessel 
complications which often resulted in hind limb paralysis and the incidence of these 
complications was similar in both groups. Most other early deaths were of 
indeterminate cause. From day 4 to day 14, 7 out of 49 animals (14%) died of 
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ureteric complications with the patch method, while 10 out of 87 animals (11%) 
with the implant method suffered ureteric complications. The implant method led 
to apparently higher levels of ureteric stenosis (Table 2), although the result was 
not statistically significant (p=0.33). In contrast, the patch method was more likely 
to cause bladder necrosis and leakage (confirmed by the presence of urine in the 
abdominal cavity and direct visualization of the ureter/bladder patch anastomosis 
site at post-mortem) (p=0.02). The majority of animals dying during this period 
succumbed to graft rejection rather than operative complications. After day 14, 
most transplanted animals survived long term with some surviving greater than 300 
days in the retrospective series (Figure 31A). Varying degrees of hydronephrosis 
were noted in some long-term surviving animals at the time of death or when 
sacrificed for tissue collection. The proportion of animals with hydronephrosis was 
equivalent in each treatment group. Median survival with the patch method was 7 
days compared to 35 days with the implant method. A higher proportion of animals 
died before day 15 in the patch group than in the implant group but this difference 
did not quite reach statistical significance (p=0.06). Overall survival assessed at 300 
days post-transplant was not different between the two methods (p=0.09) (Figure 
31A).  
The prospective analysis is shown in Figure 31B and confirmed the findings of the 
retrospective analysis. There was no significant difference in survival between the 
two groups (p=0.82) or between the survival in the retrospective versus prospective 
analysis for the patch method (p=0.29) or the implant method (p=0.51). For the 
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patch method, one animal died at day 10 with urine leak, one at day 5 with ureteric 
and bladder patch necrosis (Figure 32), one at day 4 with renal artery thrombosis 
and one at day 79 with hydronephrosis. In the implant method, one animal died at 
day 7 with possible lymphatic leakage and one at day 35 with hydronephrosis. The 
causes of death for the remaining animals in both groups could not be determined. 
The operation times for the two methods differed. The operation time for the 
donor procedure for the implant method (14.8 ±2.2 min) (n=16) was significantly 
shorter than that for the patch method (28.3±2.4) (n=16) (p<0.001). Similarly, the 
recipient operation time using the implant method (61.4±4.7) was shorter than that 
using the patch method (77.8±5.5) (p<0.001). There was no difference between the 
two methods in the time to complete the arterial (p=0.07) or venous (p=0.70) 
anastomoses, or in the graft ischaemia time (p=0.71). The average total operation 
time (donor plus recipient times) was 76 minutes/transplant for the implant 
method, while 106 minutes/transplant for the patch method. 
Because the implant method was a significantly faster operation, with outcomes at 
least as good as those of the bladder patch method, we decided to use the implant 
method for all subsequent mouse kidney transplant experiments. The ureteric 
implant procedure is described in detail in ‘Chapter 2’. 
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Table 2 Results of mouse kidney Tx with patch and implant ureteric anastomosis: 
Survival / Reason for Death Patch (n=62) Implant (n=101) p-value 
≤ 3 Days (n) (%) 13 (21.0%) 14 (13.9%) 0.28 
   Limb Paralysis 3 (4.8%) 5 (5.0%) 1.00 
   Unknown 10 (16.1%) 9 (8.9%) 0.21 
4 - 14 Days (n) (%) 23 (37.1%) 30 (29.7%) 0.39 
   Ureteric Stenosis 2 (4.1%)* 9 (10.3%)* 0.33 
   Bladder Leak 5 (10.2%)* 1 (1.1%)* 0.02** 
   Rejection 16 (32.7%)* 20 (23.0%)* 0.23 
> 14 Days (n) (%) 26 (41.9%) 57 (56.4%) 0.08 
   Hydronephrosis 4 (15.4%)* 5 (8.8%)* 0.45 
*    Expressed as the percentage of surviving animals at each time point. 
**  There are significant differences between the data compared 
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Figure 31 Animal survivals with the two different ureteric reconstruction methods. 
A. Retrospective data showing that early mortality from nonspecific causes 
appeared to be higher in the mice transplanted using the patch method than in 
those transplanted using the ureteric implant method, but thereafter survival 
curves were parallel. B. Prospective study survival data showing that there is no 
difference between the two different methods for long tern survival. 
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Figure 32 Bladder patch necrosis is an important cause of early death of mice 
following renal transplantation using the bladder patch anastomosis method. 
Ureteric reconstruction with patch method (4 days post transplantation) showing 
necrosis of the donor bladder patch and distal end of the ureter due to inadvertent 
damage to the blood supply during the operation. The vertical arrow points to the 
urine leakage site, whilst the horizontal arrow shows the necrotic patch and ureter.  
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CHAPTER 5: ESTABLISHMENT AND CHARACTERISATION OF A MURINE 
MODEL OF BRAIN DEATH INCLUDING EFFECTS UPON SYNGENEIC 
RENAL TRANSPLANTATION 
5.1 Establishment of a mouse model of brain death 
Steps in the establishment of the murine brain death model are described in 
‘Chapter 2’. Once established, the model was characterised with respect to the 
physiological parameters of the mouse, release of DAMPs such as S100B and 
HMGB1, release of cytokines and chemokines into the systemic circulation, and 
histological and biochemical markers of organ damage. 
5.2 Physiological parameters 
Many physiological parameters were measured before, during and after the 
induction of brain death. Mean arterial pressure (MAP) was measured via a femoral 
artery cannula and BP transducer. A rectal probe was used to detect the 
temperature of the mouse and a mouse pulse oxymeter with tail clip was used to 
monitor the heart rate (HR) and oxygen saturation (SO2). During brain death, a 
Cushing response was observed with a spike in MAP accompanied by tachycardia. 
The tachycardia persisted, whereas MAP slowly declined. Oxygen saturation was 
maintained throughout the experiment at close to 100%. The body temperature of 
the mice were maintained between 36.5-38oC. Recordings taken during a typical BD 
experiment are shown in Figure 33 below. 
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Figure 33 Physiological traces of a mouse maintained for a duration of 3 hours 
after the induction of brain death. At the point of BD, a peak in blood pressure 
(MAP) occurs, concurrent with an increase in heart rate (HR). MAP slowly drops 
over time, whereas tachycardia persists. IV boluses of 0.25ml Gelofusine were given 
whenever the MAP reached 40mmHg. Oxygen saturation was maintained tclose to 
100% hroughout the maintenance period. Core temperature of the mice was kept 
between 36.5-38oC. 
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5.3 Release of Damage-associated molecular patterns (DAMPs) 
Inflammatory ligands released from tissues during ischaemia and reperfusion 
include HMGB1 and S100B. We determined whether these ligands were released 
into the systemic circulation at 30 and 60 minutes, and 3 hours following the 
induction of brain death in our model, as well as in ventilated, non-BD controls. 
5.3.1 S100B 
Serum S100B is a biomarker for CNS and other tissue damage. By 30 minutes after 
the induction of brain death, an increase above baseline measurements in serum 
S100B could be observed (Figure 34). Peak levels of serum S100B (10,163+/-4775 
pg/ml) were reached three hours after the onset of brain death (P<0.05 compared 
with baseline). Serum S100B was also elevated above baseline in the mice 
ventilated for three hours (1731+/-1114 pg/ml) but the levels attained in these 
mice were significantly less than those in the BD group (P<0.05). 
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Figure 34 Timecourse of systemic S100B release after induction of brain death. 
S100B was detectable in the serum at levels above baseline from 30 minutes after 
the induction of brain death. Peak levels were reached at 3 hours after BD induction, 
and a more modest elevation in levels of S100B was also noted in the serum of 
ventilated controls at this time. n=4-6 in each group. 
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5.3.2 HMGB1 
In contrast to S100B, serum levels of HMGB1 were not appreciably increased until 
three hours after the induction of brain death (26.53+/-6.38ng/ml v/s 3.83+/-
0.98ng/ml, P<0.001) (Figure 35). While serum levels of HMGB1 increased slightly 
above baseline in ventilated controls, levels of HMGB1 in BD mice were significantly 
greater than those in control animals (8.12+/-2.1ng/ml, P <0.01). 
 
 
 
 
 
 
 
 
 
Figure 35 Timecourse of systemic HMGB1 release after induction of brain death. 
HMGB1 levels were significantly increased at 3 hours after the induction of brain 
death, compared with baseline levels and with levels in animals ventilated for three 
hours. n=4-6 in each group. 
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5.4 Release of cytokines into the systemic circulation 
Increased systemic levels of a number of pro-inflammatory cytokines and 
chemokines including IL-6, TNF-α and IL-8 have been well-documented following 
the induction of brain death. Here, we used a multiplex assay to determine levels of 
a panel of cytokines at various times following BD induction. Most of these soluble 
factors displayed a similar pattern of systemic release, with maximal or near 
maximal levels being reached by 60 minutes after BD induction (Figure 36).  
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Figure 36 Systemic release of cytokines after the induction of brain death. n=4-6 in 
each group.  
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5.5 Histological and biochemical evidence of organ damage and inflammation 
during brain death 
5.5.1 Lungs 
Given that ventilator-induced lung injury can occur, even with gentle mechanical 
ventilation, and that this can result in systemic inflammatory manifestations [174], 
we assessed the lungs histologically. In these mice which received colloid fluid 
support intravenously, there was little evidence of pulmonary oedema (data not 
shown). However, a very marked neutrophil infiltration was present in both the 
lungs from ventilated controls and was even more pronounced in brain-dead 
animals (Figure 37). 
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Figure 37 The effect of ventilation and brain death on neutrophil infiltration in 
mouse lungs. A is a normal mouse lung stained for neutrophil infiltrates. Few 
neutrophils are present; B is lung from a mouse which had undergone ventilation 
for 3 hours. Neutrophils are plentiful; C is lung from a BD mouse after 3 hours of 
maintenance in the BD state. Heavy neutrophil infiltration can be observed. 
A – Normal mouse lung B – Ventilated 3hrs 
lung
B – Ventilated 3hrs + 
BD 3hrs lung 
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5.5.2 Kidneys 
Damage to kidneys was assessed histologically, as well as by measuring the 
expression of neutrophil Gelatinase-associated lipocalin, an early biomarker of 
renal damage. The expression of genes for a range of cytokines and chemokines, as 
well as for the pattern-recognition receptors RAGE and TLR4 was measured, and 
inflammatory infiltrates of neutrophils and macrophages were detected by 
immunohistochemistry. 
5.5.2a Serum Neutrophil Gelatinase-associated Lipocalin (NGAL) 
NGAL is a sensitive biomarker for renal injury, and able to detect damage in the 
acute phase of renal injury before a rise in serum creatinine has occurred [175]. By 
60 minutes after the induction of brain death, the serum NGAL levels have clearly 
increased above the baseline of to a level >1000µg/ml (1142+/-220µg/ml, P=0.0026) 
(Figure 38). The maximum serum NGAL level was reached at three hours after the 
onset of brain death (5990+/-7035µg/ml). Levels of NGAL are also elevated above 
baseline in the ventilated controls after three hours (455+/-345µg/ml) but this rise 
is modest in comparison to that in BD animals (P=0.015). 
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Figure 38 Timecourse of serum NGAL after induction of brain death. Serum levels 
of NGAL had risen substantially by 60 minutes after the induction of brain death 
and were further elevated at the 3-hour sampling point. A modest elevation in 
serum NGAL was found in ventilated controls after 3 hours. n=4-6 in each group. 
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5.5.2b Expression of pattern-recognition receptors 
Increased expression of pattern recognition receptors in kidneys following 
ischaemia reperfusion injury has been widely reported [42, 44]. We used RT-PCR to 
determine whether upregulation of RAGE and TLR4 could be detected in mouse 
kidneys soon after induction of brain death. We were surprised to find that, if 
anything, mRNA expression for these genes appeared to be decreased by three 
hours after the induction of BD. A similar decrease was seen for ventilated controls, 
suggesting that this effect may have resulted from prolonged anaesthesia or 
mechanical ventilation (Figure 39 below). 
 
 
Figure 39 Gene expression for pattern-recognition receptors in kidneys during 
brain death. n=3-6 in each group. 
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5.5.2c Expression of cytokines and other soluble mediators 
Gene expression (mRNA levels) for the chemokines CXCL10, KC, MCP1, MIP2, and 
CCL22 follows a similar pattern whereby the peak of expression is reached by 1 
hour after the onset of brain death. Expression of CCL17 started to rise earlier than 
the other chemokines (Figure 40 below). Cytokines with pro-inflammatory activity, 
such as IL-6, IL-1β and TNF-α had attained maximum expression by 60 minutes after 
the induction of brain death, as had those with reported immunomodulatory 
activity (IL10, TGF-β) (Figure 41).  
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Figure 40 Chemokine gene expression in kidneys following the induction of brain 
death. The following genes were analysed within the kidneys: CXCL10, KC, MCP1, 
MIP2, CCL17 and CCL22. All had reached peak expression within one after the 
induction of BD. n=3-4 in each group. 
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Figure 41 Cytokine gene expression in kidneys following the induction of brain 
death. The following genes were analysed within the kidneys: IL10, TGF-β, IL6, IL1β, 
HSP2 and TNF-α. Similar to the chemokine genes examined, all had reached peak 
expression within one after the induction of BD. n=3-4 in each group. 
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5.5.2d Neutrophil infiltration within the kidneys of mice following brain death 
Histological changes lag behind changes in gene expression, and whereas the 
neutrophil chemokine KC was upregulated in renal tissue and in serum at 60 
minutes after the onset of BD, neutrophils were not detected in the kidneys of mice 
at times earlier than 3 hours post-BD. It can be seen from Figure 42 that there are 
significantly more neutrophils in kidneys from mice at 3hour post-BD (8.8+/-5.6 
cells per high powered viewing field) than ventilated controls kidneys (1.9+/-1.6 cell 
per high powered viewing field, P=0.03). 
 
 
Figure 42 Neutrophil infiltration of kidneys at 3 hours after induction of BD. There 
are significantly more neutrophils in kidneys from BD mice at 3 hours than in 
ventilated controls and normal controls. n=4-6 in each group. * indicates significant 
differences between the compared groups (P-value <0.05).   
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5.5.2e Macrophage infiltration within the kidneys 
No one epitope is able to identify all subsets of macrophages in mice. Antibodies 
recognising two different epitopes (CD68 and F4/80) were used for macrophage 
detection. Normal kidneys have a substantial population of resident macrophages 
(13.7+/- 6.9/HPF, Figure 43A, and 16.3+/-2.8/HPF, Figure 43B). A modest increase in 
macrophage numbers above this baseline was noted in kidneys after 3 hours of BD 
using either antibody (F4/80: 23.3+/-10.1/HPF, P=0.03; CD68: 25.3+/-7.6/HPF, 
P=0.005). CD68 but not F4/80 staining also identified a small increase in 
macrophage numbers in the kidneys from ventilated control mice (22+/-4.8/HPF, 
P=0.005) (Figure 43B). 
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Figure 43 Macrophages within the kidneys of mice after brain death. A and C: 
staining with F4/80, B: staining with CD68. Based on F4/80 staining, there is a 
modest increase in macrophages in the kidneys of BD mice compared with the 
normal baseline. CD68 indentified a slight increase in renal macrophage numbers in 
ventilated controls as well as in BD mice. n=4-6 in each group. For A and B, * 
indicates significant differences between the compared groups (P-value <0.05).   
A B 
BD 3hrs 
Vent only 3hrs Normal B6 
C 
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5.5.2f Kidney Morphology 
H&E stained sections of kidneys were examined for morphological evidence of 
damage to kidneys during brain death. Kidneys from BD mice after 3 hours of 
maintenance showed evidence of some tubular vacuolation and a mild increase in 
interstitial inflammatory infiltrate, when compared with normal mouse kidneys 
(Figure 44 A and B). Because it is not feasible to attempt to maintain mice for longer 
than 3 hours after the induction of brain death, kidneys from BD mice were 
collected after 3 hours of maintenance, then transplanted into syngeneic recipients. 
At D4 after syngeneic transplantation, these kidneys show features of acute tubular 
necrosis (ATN), with loss of tubular nuclei and a mixed infiltrate including 
neutrophils and mononuclear cells, Figure 44D. The extent of renal damage in these 
kidneys appeared substantially greater than that in kidneys transplanted from 
control donors into syngeneic recipients (Figure 44C), making it uncertain whether 
these kidneys would be able to support life in later planned experiments following 
the removal of the contralateral native kidney on post-operative d4. 
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Figure 44 Histological appearances of normal kidney, and kidney at various stages 
after BD induction and/or renal transplantation. A: normal kidney; B: kidney at 3 
hours after induction of BD shows some evidence of tubular vacuolation and a mild 
increase in interstitial inflammatory infiltrate; C: kidney at day 4 after syngeneic 
transplantation from a control donor shows tubular dilatation and occasional 
protein cast formation; D: kidney at day 4 after syngeneic transplantation from a 
brain dead donor (maintenance period 3 hours) displays features of ATN, with loss 
of tubular nuclei and a mixed infiltrate including neutrophils and mononuclear cells.  
A – Normal kidney B – BD 3hrs 
C – Syngeneic KTx D4 D – Syngeneic KTx D4 
+ BD donor 3hrs 
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Because of the rapid kinetics of inflammatory cytokine release we had observed in 
BD mice, and because the early rise in NGAL provided evidence that the process of 
renal damage had already commenced by one hour after BD onset, we modified 
our experimental protocol to collect and transplant kidneys at one hour after BD 
induction. This change resulted in many more viable renal tubules in kidneys 
collected at d4 after syngeneic transplantation (Figure 45 panel C v/s panel B). In 
contrast, the extent of neutrophil infiltration was similar between kidneys 
transplanted after 3 hours of maintenance or one hour of maintenance and in both 
instances greatly exceeded neutrophil infiltration in syngeneic transplants from 
control donors (Figure 46), suggesting that the proinflammatory effect of brain 
death upon renal transplantation would still be observed with the shorter 
maintenance period.  
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Figure 45 Appearances of syngeneic kidney transplants from BD donors following 
either 1 hr or 3 hours of maintenance.  
A- Syngeneic KTx D4 
B- Syngeneic KTx D4 
+ BD Donor 3hrs 
C- Syngeneic KTx D4  
+ BD Donor 1hr 
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Figure 46 Neutrophil infiltration of syngeneic renal transplants from BD donors 
maintained for 1 hour or 3 hours following induction of brain death. 
 
  
A- Syngeneic KTx D4 
B- Syngeneic KTx D4 
+ BD Donor 3hrs 
C- Syngeneic KTx D4  
+ BD Donor 1hr 
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5.6 Effects of brain death combined with syngeneic renal transplantation 
For these experiments, mice were maintained for one hour following induction of 
brain death. Kidneys were collected and transplanted into syngeneic recipients, and 
tissues were harvested one or four days after renal transplantation. 
5.6.1 Upregulation of pattern-recognition receptors within the kidneys 
TLR4 expression following syngeneic transplantation was increased in kidneys from 
BD donors when compared to those from control donors on both d1 (median 61.63 
v/s 34.21) and d4 (median 140.6 v/s 59.7) post-transplantation. In the case of RAGE, 
an increase in mRNA levels in kidneys from BD donors was only noted on d4 
(median 110.8 v/s 24.5) (Figure 47).  
 
Figure 47 Expression of pattern recognition receptors following brain death and 
syngeneic renal transplantation. n=4-6 in each group. 
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5.6.2 Upregulation of chemokine gene expression following brain death and 
syngeneic transplantation. 
Expression of all the chemokines examined was increased in kidneys following 
syngeneic renal transplantation from control donors, when compared with levels in 
normal mouse kidneys. In most instances, there was a further increase in 
expression levels when kidneys from brain dead donors were transplanted. This 
was particularly marked for CXCL10 (median 104.9 v/s 14.39, P=0.02) and CCL22 
(median 39.1 v/s 3.35, P+0.04) on d1, and MCP-1 (median on 250 v/s 32.43, P=0.02) 
d4 (Figure 48). CCL22 was the only chemokine where mRNA levels were not 
increased in kidneys from BD donors above those in control kidneys on d4 post-
transplantation. 
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Figure 48 Expression of chemokine genes after brain death and syngeneic renal 
transplantation. n=4-6 in each group. 
116 
 
 
 
5.6.3 Expression of genes for cytokines and other soluble mediators following 
donor brain death and syngeneic renal transplantation. 
IL-6 mRNA expression increased considerably by d1 post-transplant in syngeneic 
kidneys transplanted from control donors (median 7.6 v/s 0.21, P=0.03), with a 
further increase noted in kidneys transplanted from brain-dead donors (median 
13.56). The pattern of expression for TNF-α was similar, whereas levels of TGF-β, IL-
1β and HSP2 did not change substantially in grafts from control donors, but were 
upregulated on both days 1 and 4 post-transplant in kidneys from BD donors. IL-10 
was unusual in that expression in BD donor kidneys on d4 was no greater than that 
in control kidneys (Figure 49). 
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Figure 49 Expression of cytokines and other soluble mediators after brain death 
and syngeneic renal transplantation. n=4-6 in each group. 
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5.6.4 Neutrophil infiltration within control kidneys and those from BD donors 
Normal mouse kidneys contained no neutrophils. A mild neutrophil infiltrate was 
present in control kidneys (0.8+/-1.0 cells/HPF on d1 and 1.4+/-1.1 cells/HPF on d4 
post transplantation). The extent of neutrophil infiltration was dramatically 
increased in kidneys from BD donors on d4 post-transplantation (23.1+/-19.0, 
P=0.006) (Figure 50). 
 
Figure 50 Neutrophil infiltration following brain death and syngeneic renal 
transplantation. Numbers of infiltrating neutrophils in kidneys from BD donors 
were significantly increased compared to those from control donors on d4 post-
transplantation. n=4-6 in each group. * indicates significant differences in the 
compared groups (P-value <0.05).  
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5.6.5 Macrophage infiltration in control kidneys and those from BD donors 
As above, both CD68 and F4/80 were used to identify macrophages within 
transplanted kidneys.  Using F4/80, the number of resident macrophages in normal 
kidneys was 13.7+/-6.88 cells/HPF. Whereas there appeared to be a slight increase 
in the number of macrophages present within the kidneys after syngeneic 
transplantation from control donors (18.5+/-7.7 at d1 and 23.7+/-16.4 at d4, P=NS), 
many more infiltrating macrophages were detected in the kidneys transplanted 
from BD donors (38.2+/-12 cells/HPF on d1, P=0.02 and 65.1+/-24.1 on d4, P=0.03) 
(Figure 51A). These results were paralleled by those obtained with CD68 staining. 
Representative sections are shown below (Figure 51B). 
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Figure 51 Macrophage infiltration following brain death and syngeneic renal 
transplantation. Increased numbers of macrophages are detected in kidneys from 
BD donors compared with those from control donors at both d1 and d4 after 
syngeneic renal transplantation using either F4/80 (A) or CD68 (B). n=4-6 in each 
group. For A, * indicates significant differences between the compared groups (P-
value <0.05).   
Syn KTx D1 Syn KTx D1 + BD 
1hr
  Syn KTx D4 + BD 1hr Syn KTx D4 
A 
B 
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CHAPTER 6: MODULATION OF INFLAMMATORY RESPONSES AFTER 
BRAIN DEATH AND SYNGENEIC RENAL TRANSPLANTATION BY 
SYSTEMIC OVEREXPRESSION OF esRAGE. 
Having determined that donor brain death resulted in increased expression of 
inflammatory markers and increased infiltration of kidneys by neutrophils and 
macrophages both prior to and following subsequent syngeneic renal 
transplantation, we then evaluated whether systemic overexpression of esRAGE in 
the kidney donor and recipient could modulate inflammation in this setting. 
6.1 Systemic esRAGE expression reduces circulating levels of HMGB1 after brain 
death. 
Figure 52 shows the serum HMGB1 concentration for mice at 3 hours following the 
onset of brain death, ventilated controls and mice which had been injected with 
either rAAV-esRAGE or the control vector rAAV-HAS 7 days prior to BD induction. 
HMGB1 concentrations are significantly elevated (>25ng/ml) at 3 hours after 
induction of BD, compared to those in ventilated controls (<10ng/ml). BD mice 
injected with esRAGE had serum HMGB1 levels (~10ng/ml) approximating those in 
ventilated controls. However, we noted that levels of HMGB1 were reduced by a 
comparable amount in mice injected with the control vector rAAV-HSA. Albumin 
binds many substances in plasma, and because these may include lignads for RAGE 
and Toll-like receptors, rAAV-HSA may not be the most appropriate control vector 
for rAAV-esRAGE. In the later series of experiments examining the effects of 
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esRAGE expression upon kidneys after BD and syngeneic transplantation, we 
decided to use rAAV-GFP as an alternative control for rAAV-esRAGE. 
 
 
Figure 52 Serum HMGB1 levels. n=4-6 in each group. 
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6.2 Effect of esRAGE on the expression of genes for the pattern recognition 
receptors RAGE and TLR4 in kidney. 
Reduction in availability of RAGE ligands has been reported to reduce RAGE 
expression [85]. High-level systemic  expression of esRAGE modestly reduced mRNA 
expression of both RAGE (9.38+/-1.4 cf 19.8+/-6.6, P=0.048) and TLR4 (18.46+/-4.83 
cf 39.35+/-10.41, P=0.02) (Figure 53 below). mRNA levels for RAGE and TLR4 
remained low in uninjected mice at 3 hours after induction of BD, and this was not 
affected by esRAGE expression (data not shown). 
 
Figure 53 Systemic expression of esRAGE is associated with a modest reduction in 
mRNA expression for RAGE and TLR4 in kidney. n=4-6 in each group. * indicates 
significant differences between the compared groups (P-value <0.05).  
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6.3 The effect of esRAGE upon mRNA expression for chemokines, cytokines and 
other soluble mediators in kidney after brain death. 
There was a wide scatter in the results for gene expression of chemokines, 
cytokines and other soluble mediators in kidneys at 3 hours following induction of 
brain death, including those from mice treated with esRAGE or control vector. 
Although there was a trend towards reduction in the median levels of expression 
for many of these mediators in mice treated with esRAGE, none of the differences 
between treatment groups reached statistical significance (Figures 44-55). 
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Figure 54 Cytokine gene expression in kidneys of BD with/without esRAGE. n=3-5 
in each group. 
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Figure 55 Cytokine gene expression in kidneys of BD with/without esRAGE. n=3-5 
in each group. 
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6.4 Expression of esRAGE reduces renal neutrophil infiltration after brain death 
No neutrophil infiltrate was observed in normal C57BL/6 mice, nor in normal 
C57BL/6 injected with esRAGE or control vector, (Figure 56). Numbers of infiltrating 
neutrophils were significantly reduced in BD mice expressing esRAGE (4.1+/-2.5 
cells/HPF), compared with uninjected BD mice (8.8+/-5.6 cells/HPF, P=0.035).   
 
Figure 56 Renal neutrophil cell counts with/without brain death and esRAGE.  
There are significantly less neutrophils in the kidneys of mice injected with esRAGE 
than in those of their uninjected counterparts. n=4-6 in each group. * indicates 
significant differences in the compared groups (P-value <0.05).  
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6.5 esRAGE expression reduces macrophage infiltration of kidneys following brain 
death. 
Both F4/80 and CD68 were used for the identification of macrophages in the 
kidneys from normal mice and those which had undergone brain death and a three-
hour maintenance period. F4/80-positive macrophages/HPF increased from 13.7+/-
6.9 in the kidneys of normal mice to 23.3+/-10.3 at 3 hours after BD.  Numbers 
were similar in BD mice treated with control vector (28.00+/-12.7, P=NS) but were 
reduced to approximate those in normal mice (13.10+/-7.8, P= 0.008) compared 
with untreated or control (vector-treated BD) by expression of esRAGE (Figure 57A, 
below). The same pattern was observed when CD68 was used for macrophage 
detection (see representative sections below (Figure 57B). 
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Figure 57 esRAGE expression reduces renal macrophage infiltration following 
brain death. (A) results obtained using F4/80 for macrophage detection, (B) parallel 
findings when CD68 is used to identify macrophages. n=4-6 in each group. For A, * 
indicates significant differences between the compared groups (P-value <0.05). 
BD 3hrs BD 3hrs + control 
BD 3hrs + esRAGE 
A 
B 
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6.6 The effects of esRAGE upon donor kidneys under conditions of brain death 
and syngeneic renal transplantation. 
The ability of esRAGE expression to attenuate inflammation in donor kidneys 
following brain death and syngeneic renal transplantation was next determined. 
6.6.1 mRNA expression for pattern-recognition receptors within the kidneys 
mRNA expression levels for RAGE and TLR4 were examined at d1 and d4 following 
syngeneic renal transplantation. Again, a wide scatter in results was observed. 
There was a trend towards reduction of expression of these receptors in mice 
treated with esRAGE vector which was more prominent at d4 post-transplantation 
(RAGE median 110.8 v /s 59.83, TLR4 median 140.6 v/s 80.4). These changes did not 
reach statistical significance (Figure 58). 
       
 
Figure 58 Expression of pattern-recognition receptors on d4 following renal 
transplantation. n=4-6 in each group.
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6.6.2 The effect of esRAGE upon mRNA expression for chemokines, cytokines and 
other soluble mediators in kidney after syngeneic renal transplantation from 
brain dead donors. 
esRAGE expression did not result in significant reduction of mRNA levels for most of 
the chemokines and cytokines examined in kidneys at either one or four days 
following syngeneic renal transplantation from brain dead donors (Figures 59 A, B, 
C, D below) though as noted above there was  a broad scatter of results.  
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Figure 59 No cytokine reduction following syngeneic renal transplantation from 
brain dead donors following the injection of esRAGE (A, B, C and D). n=4-6 in each 
group. 
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6.6.3 esRAGE expression reduces neutrophil infiltration in kidneys on d4 after 
syngeneic renal transplantation from brain dead donors. 
Figure 60 shows that the mild neutrophil infiltration was not reduced by esRAGE 
expression in kidneys from BD donors at d1 following syngeneic renal 
transplantation (Figure 60A). A more intense neutrophil infiltrate was present on d4 
post-transplantation, and the density of this infiltrate was reduced by esRAGE 
expression (23.1+/-19 cf 9.1+/-8.7, P=0.027). 
 
 
Figure 60 Neutrophil cell counts for kidneys from BD donors at d1 (A) and 4 (B) 
after syngeneic renal transplantation. n=4-6 in each group. * indicates significant 
differences between the compared groups (P-value <0.05).  
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6.6.4 esRAGE expression reduces macrophage infiltration in kidneys from brain 
dead donors at days 1 and 4 after syngeneic renal transplantation.  
Both F4/80 and CD68 were used to enumerate macrophages in the kidneys from 
mice in these treatment groups. The number of F4/80-positive macrophages 
infiltrating kidneys was reduced significantly by esRAGE expression on both d1 post-
transplantation (18.8+/-3.5 cf  38.2+/-14, P=0.019, Figure 61A) and d4 post-
transplantation (27.3+/-7.9 cf 65.1+/-24.1, P=0.005, Figure 61B). Results obtained 
with CD68 parallelled these changes (representative sections from d4 post-
transplantation shown in Figure 61C below) 
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Figure 61 Numbers of infiltrating macrophages in kidneys from brain dead donors 
following syngeneic renal transplantation are reduced by esRAGE expression. A - 
F4/80, d1 post-transplantation; B - F4/80 d4 post-transplantation; C - CD68 d4 post-
transplantation. n=4-6 in each group. For A and B, * indicates significant differences 
between the compared groups (P-value <0.05). 
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6.6.5 Hypercellular appearance of kidneys from mice expressing esRAGE is likely 
to be the result of renal cell proliferation rather than inflammatory cell infiltration. 
Although infiltrating neutrophils and macrophages were significantly less common 
in the kidneys of mice expressing esRAGE at d4 following syngeneic transplantation 
from a BD donor, than in those from uninjected mice, the kidneys of both groups of 
mice had a similar hypercellular appearance on H and E stained sections (Figure 62, 
below). Further stains were performed to try and determine whether this 
appearance was the result of infiltrating CD4+ or CD8+ T cells, or of proliferation of 
intrinsic renal cells. Proliferating cells were identified using an antibody against 
proliferating cell nuclear antigen (PCNA). From Figure 70, it can be seen that there 
are significantly more PCNA-positive cells in the esRAGE-injected group when 
compared to its non-injected counterpart (7.6+/-1.1 cf 4.2+/-2.7, P=0.047). This 
difference is even more striking when cell counts from esRAGE-expressing mice are 
compared with those from mice treated with the control vector (0.23+/-0.06, 
P=0.0008). 
             
Figure 62 Similar H&E appearance of the kidneys of mice expressing esRAGE and 
uninjected control at d4 following syngeneic transplantation from a BD donor.
Syn Tx D4 + BD 1hr Syn Tx D4 + BD 1hr + esRAGE 
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Figure 63 esRAGE expression significantly increases the number of proliferating 
cells in kidneys at d4 after syngeneic renal transplantation from BD donors. There 
are significantly more PCNA-positive cells in the esRAGE-injected group than in the 
non-injected group or the control-injected group. n=4-6 in each group. * indicates 
significant differences between the compared groups (P-value <0.05). 
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In contrast, Figure 64 shows that there are no significant differences in CD4 cell 
counts in kidneys between these groups. 
 
 
Figure 64 CD4 cell counts for kidneys at d4 following syngeneic renal 
transplantation from BD donors. There are no significant differences between the 
groups. n=4-6 in each group. 
 
Immunochemical staining for FoxP3 and CD8a cells was negative for all samples. 
The positive controls for both FoxP3 and CD8a were stained positive. 
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CHAPTER 7: DISCUSSION 
In this project, we have established a mouse model of brain death and subsequent 
renal transplantation. Whilst it is only possible to maintain mice for a relatively 
short period after the induction of brain death, this extension of the brain death 
model more closely resembles the setting of clinical transplantation than models of 
warm IRI utilizing vascular clamping and release. We showed that brain death in 
this model was accompanied by the expected physiological changes [176] and that 
as reported for other similar models [16, 176], a systemic pro-inflammatory state 
ensues, with release of alarmins including S100B and HMGB1, and rapid elevation 
in circulating levels of cytokines and chemokines such as IL-6, TNF-α, IL-1β, MCP-1 
and KC. Structural changes in kidneys at this stage include some tubular vacuolation 
and a mild inflammatory infiltrate, and biochemical evidence of kidney damage is 
provided by increased serum concentrations of NGAL, an early biomarker of acute 
kidney injury [177]. Release of HMGB1 followed a different timecourse to that 
which is described following warm renal or liver ischaemia and reperfusion [43, 77, 
170]. In those settings, HMGB1 release peaks at 10-15 minutes after organ 
reperfusion, whereas in this model, peak levels were not attained until 3 hours 
after BD induction. This difference in tempo may be due to the fact that while 
perfusion of transplantable organs is erratic following BD, it is not completely 
interrupted and then restored as occurs in vascular occlusion models. Conversely, 
increased levels of S100B are noted in the systemic circulation within 30 minutes 
after the onset of BD, although they continue to rise through the three-hour 
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maintenance period. This may be reflective of the dual origin of S100B. The CNS is 
particularly rich in S100B, which is released into the systemic circulation as the 
brain is being injured by the progressive rise in intracranial pressure which 
accompanies intracranial balloon inflation in this model. When brain death occurs, 
cerebral blood circulation ceases, and S100B release is then the consequence of the 
supervening damage to other organs and tissues.  
After determining the optimum method for ureteric reconstruction, we collected 
kidneys from BD donors, and performed syngeneic renal transplants to examine 
how donor brain death amplifies the ischaemia-reperfusion injury which inevitably 
accompanies any transplantation procedure. As anticipated, we found that donor 
brain death resulted in upregulation of a number of pro-inflammatory cytokines 
and chemokines in transplanted kidneys, and in substantially increased infiltration 
with neutrophils and macrophages. As distinct from mouse models of warm renal 
ischaemia and reperfusion, where ischaemia is achieved through clamping the renal 
pedicles [44], neutrophil infiltration was greatest on d4 post-transplantation, similar 
to the tempo of infiltration with macrophages. These findings parallel the 
timecourse of gene expression for the neutrophil chemokine KC and the 
macrophage chemokine MCP-1, where peak expression of both chemokines was 
achieved at d4 post-transplantation (Chapter 5 Figure 48).  
Signalling through pattern-recognition receptors such as TLR2 and TLR4 is critical for 
the propogation of inflammation following an ischaemic insult to the kidneys [42, 
44]. esRAGE is a naturally-occurring soluble isoform of RAGE [178]. esRAGE can 
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exert anti-inflammatory effects via the binding and sequestration of circulating 
ligands such as S100B and HMGB1. Because HMGB1 is a common ligand for TLRs 2, 
4 and 9, as well as for RAGE [50, 54, 55], HMGB1 binding by esRAGE can interfere 
with signaling through all these receptors. In addition to its activity as a decoy 
receptor, esRAGE can also directly block RAGE signaling by forming heterodimers 
with cell-surface RAGE and thus preventing RAGE dimerization which is a necessary 
precursor to signal transduction [85, 89]. 
In order to study the effects of esRAGE upon IRI in brain-death and subsequent 
syngeneic renal transplantation, we generated an rAAV vector encoding esRAGE. 
Intraperitoneal injection of this vector resulted in strong, liver-specific expression of 
esRAGE. Secreted esRAGE protein was detected at high levels in the systemic 
circulation from d2 until at least d100 following IP injection, and was well tolerated 
with no evidence of liver inflammation. Substantial concentrations of human 
esRAGE were present in the heart, kidneys and spleen, as well as the liver and 
serum of transduced animals. The rAAV2/8 vector system is an efficient means of 
gene transfer to liver [162]. The vector is minimally immunogenic, and 
immunological tolerance to the transgene product has been formally demonstrated 
on a number of occasions, including in a stringent skin transplant model [169]. The 
achievement of long-lived, high-level esRAGE expression using this system is in line 
with these previous reports.  
The most striking effect of esRAGE expression in mice undergoing brain death and 
syngeneic renal transplantation was a dramatic reduction in the numbers of 
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infiltrating neutrophils and macrophages within the kidneys. Several factors may 
contribute to this. Expression of KC (the murine orthologue of IL-8) and of MCP-1, 
was reduced modestly, if at all, in the kidneys of esRAGE–injected mice after BD 
and renal transplantation. However, RAGE is a known binding partner for the 
leucocyte integrin MAC-1 [84, 102], and reduction of leucocyte infiltration in the 
presence of esRAGE may represent an effect of direct inhibition of this interaction. 
Neither TNF-α nor IL-6 levels were reduced by esRAGE expression in kidneys from 
BD donors after syngeneic transplantation, although a modest reduction was 
apparent in the kidneys of BD mice treated with esRAGE vector. Although these 
cytokines are pro-inflammatory, TNF-α also has an important pro-survival effect on 
ischaemic organs, reducing the numbers of cells undergoing apoptosis and 
increasing proliferation as measured by the number of nuclei positive for PCNA [92]. 
Administration of recombinant soluble RAGE to mice undergoing warm liver 
ischaemia and reperfusion resulted in a survival advantage which was accompanied 
by increased mRNA transcripts for TNF-α, and by increased proliferation of 
parenchymal cells following the injury [92]. Similarly, substantially increased 
numbers of proliferating cells were demonstrated in the kidneys of esRAGE-treated 
mice at d4 after syngeneic transplantation from BD donors, compared with those of 
uninjected mice and particularly with those of mice receiving the control vector 
(Chapter 6, Figure 63). Given that the grafts from esRAGE–treated mice had 
reduced numbers of infiltrating leucocytes compared to those in the other groups, 
it is likely that this represents proliferation of renal parenchymal cells in the 
transplanted kidneys.   
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In conclusion, we have developed a clinically-relevant model for the study of the 
early inflammatory events which accompany deceased donor renal transplantation. 
The ability of rAAV-mediated systemic expression of esRAGE to attenuate this 
inflammation was assessed during brain death and after transplantation of the 
kidneys from BD donors, and the principal findings were that esRAGE reduced 
infiltration by neutrophils and macrophages and increased the proliferation of renal 
parenchymal cells in the graft post-transplantation. These effects are likely to be 
translated into improved graft function, and augmented ability of the graft to 
sustain life. RAGE signaling on T cells contributes to adaptive immune responses, 
including alloresponses [179]. Testing of esRAGE at later timepoints when the 
transplanted kidneys are life-sustaining and in allotransplant models where its 
effects upon the adaptive immune response are predicted to be additive to those 
on non-antigen-specific graft inflammation is the logical next step for this line of 
investigation, and will shortly be undertaken.  
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APPENDIX: COMPOSITION OF SOLUTIONS 
1x PBS 
1x PBS was used for the experiments, however, the stock solution was made up to 
10x and then diluted down before use. For 10x PBS, 80g of NaCI (UNIVAR), 2g of KCI 
(UNIVAR), 14.4g of Na2HPO4 (Sigma), 2.4g of KH2PO4 (AnalaR) were added to 1L of 
TDW and adjusted to pH 7.4. 
1x TBS/Tween 
1x TBST was used for the experiments, however, the stock solution was made up to 
10x and then diluted down before use. For 10x TBST, to 1L of TDW, 13.9g of Tris 
base (Sigma), 60.6g of Tris HCI (Sigma), 60.6g of NaCI (UNIVAR) and 5ml of Tween 
20 (AMRESCO) was added and adjusted to pH 7.4. 
IP diluent 
IP diluent was made by mixing together 47.25ml of 1x TBST, 2.5ml of heat-
inactivated swine serum, 0.25ml of 18% sodium azide (AnalaR), and then filtered 
through 0.22µm, and stored at 4oC for use. 
Tris buffer 
1.39g of Tris base (Sigma), 6.06g of Tris HCI (Sigma), 6.06g of NaCI (UNIVAR) were 
mixed in 1L of TDW and adjusted to pH9. 
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Citrate Buffer 
2.94g of tri-sodium citrate (dihydrate) (Sigma) was added to 1000ml of TWD and 
then adjusted to pH6. 
DEPC water 
The DEPC water used was 0.1% DEPC water. It was made by adding 0.5ml of DEPC 
solution (Sigma) to 500ml of TDW and treated by autoclaving or heating at 70oC for 
1 hour or 60oC overnight. 
0.1% v/v Triton-X-100 in 0.1% w/v Na citrate 
5ml of 2% sodium citrate (2g in 100ml TDW) (Sigma) was added to 95ml TDW and 
100µl of Triton-X-100 (Sigma). 
 
 
